EP4127201A1 - Process of engineering an oleaginous microorganism - Google Patents
Process of engineering an oleaginous microorganismInfo
- Publication number
- EP4127201A1 EP4127201A1 EP21722286.8A EP21722286A EP4127201A1 EP 4127201 A1 EP4127201 A1 EP 4127201A1 EP 21722286 A EP21722286 A EP 21722286A EP 4127201 A1 EP4127201 A1 EP 4127201A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oleaginous
- oleaginous microorganism
- seq
- oil
- engineering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 32
- 230000008569 process Effects 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 28
- 239000002028 Biomass Substances 0.000 claims abstract description 24
- 239000001963 growth medium Substances 0.000 claims abstract description 9
- 239000003921 oil Substances 0.000 claims description 109
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 39
- 241001149691 Lipomyces starkeyi Species 0.000 claims description 35
- 150000002632 lipids Chemical class 0.000 claims description 35
- 108010087894 Fatty acid desaturases Proteins 0.000 claims description 27
- 101150113476 OLE1 gene Proteins 0.000 claims description 23
- 101100188627 Zea mays OLE16 gene Proteins 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 241000221523 Rhodotorula toruloides Species 0.000 claims description 10
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 241000124105 Isochrysis sp. Species 0.000 claims description 4
- 241000223252 Rhodotorula Species 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 240000009108 Chlorella vulgaris Species 0.000 claims description 3
- 235000007089 Chlorella vulgaris Nutrition 0.000 claims description 3
- 241000580885 Cutaneotrichosporon curvatus Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 241000195645 Auxenochlorella protothecoides Species 0.000 claims description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 claims description 2
- 241000091752 Chaetoceros calcitrans Species 0.000 claims description 2
- 241001086210 Chaetoceros gracilis Species 0.000 claims description 2
- 241000091751 Chaetoceros muellerii Species 0.000 claims description 2
- 241000221751 Claviceps purpurea Species 0.000 claims description 2
- 241000199912 Crypthecodinium cohnii Species 0.000 claims description 2
- 241001527609 Cryptococcus Species 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 241001560459 Dunaliella sp. Species 0.000 claims description 2
- 241000362749 Ettlia oleoabundans Species 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 241000178290 Geotrichum fermentans Species 0.000 claims description 2
- 241000168517 Haematococcus lacustris Species 0.000 claims description 2
- 241001078425 Isochrysis zhanjiangensis Species 0.000 claims description 2
- 241001149698 Lipomyces Species 0.000 claims description 2
- 241000907999 Mortierella alpina Species 0.000 claims description 2
- 241000224474 Nannochloropsis Species 0.000 claims description 2
- 241000159660 Nannochloropsis oculata Species 0.000 claims description 2
- 241000509521 Nannochloropsis sp. Species 0.000 claims description 2
- 241000195644 Neochloris Species 0.000 claims description 2
- 241000180701 Nitzschia <flatworm> Species 0.000 claims description 2
- 241000206744 Phaeodactylum tricornutum Species 0.000 claims description 2
- 241000195648 Pseudochlorella pringsheimii Species 0.000 claims description 2
- 241000825199 Rebecca salina Species 0.000 claims description 2
- 241001303058 Rhodomonas sp. Species 0.000 claims description 2
- 241000223253 Rhodotorula glutinis Species 0.000 claims description 2
- 244000249201 Scenedesmus obliquus Species 0.000 claims description 2
- 235000007122 Scenedesmus obliquus Nutrition 0.000 claims description 2
- 241000604181 Skeletonema sp. Species 0.000 claims description 2
- 235000021536 Sugar beet Nutrition 0.000 claims description 2
- 241000196321 Tetraselmis Species 0.000 claims description 2
- 241000894100 Tetraselmis chuii Species 0.000 claims description 2
- 241000450725 Tetraselmis tetrathele Species 0.000 claims description 2
- 241001491687 Thalassiosira pseudonana Species 0.000 claims description 2
- 241000893097 Tolyposporium Species 0.000 claims description 2
- 241000223230 Trichosporon Species 0.000 claims description 2
- 241000306282 Umbelopsis isabellina Species 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 241000235013 Yarrowia Species 0.000 claims description 2
- 241000235015 Yarrowia lipolytica Species 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 235000013379 molasses Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000002699 waste material Substances 0.000 claims description 2
- 239000002351 wastewater Substances 0.000 claims description 2
- 102100034543 Fatty acid desaturase 3 Human genes 0.000 claims 2
- 241000957276 Thalassiosira weissflogii Species 0.000 claims 1
- 235000019198 oils Nutrition 0.000 description 105
- 210000004027 cell Anatomy 0.000 description 42
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 35
- 239000013598 vector Substances 0.000 description 34
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 239000002609 medium Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 230000000813 microbial effect Effects 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 18
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 17
- 108091034117 Oligonucleotide Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 238000000855 fermentation Methods 0.000 description 17
- 230000004151 fermentation Effects 0.000 description 17
- 229940097277 hygromycin b Drugs 0.000 description 17
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 230000012010 growth Effects 0.000 description 14
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 239000011543 agarose gel Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000012808 pre-inoculation Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 8
- 229940041514 candida albicans extract Drugs 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000012138 yeast extract Substances 0.000 description 8
- 239000007836 KH2PO4 Substances 0.000 description 7
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 description 7
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000005809 transesterification reaction Methods 0.000 description 7
- 208000027066 STING-associated vasculopathy with onset in infancy Diseases 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000003225 biodiesel Substances 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000004817 gas chromatography Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 235000011149 sulphuric acid Nutrition 0.000 description 6
- 229910000368 zinc sulfate Inorganic materials 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 5
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 5
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000002551 biofuel Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 3
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004513 Bacterial RNA Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101150058769 FAD2 gene Proteins 0.000 description 2
- 108020004460 Fungal RNA Proteins 0.000 description 2
- 101150094690 GAL1 gene Proteins 0.000 description 2
- 102100028501 Galanin peptides Human genes 0.000 description 2
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 2
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000010734 process oil Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000195651 Chlorella sp. Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102000009114 Fatty acid desaturases Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241001491691 Thalassiosira Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000235029 Zygosaccharomyces bailii Species 0.000 description 1
- WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019877 cocoa butter equivalent Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011234 economic evaluation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 101150029559 hph gene Proteins 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 239000010841 municipal wastewater Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 101150087123 nat gene Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000010801 sewage sludge Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- -1 sterol esters Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/19—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
- C12Y114/19001—Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6458—Glycerides by transesterification, e.g. interesterification, ester interchange, alcoholysis or acidolysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6463—Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Definitions
- the present invention relates to a process of engineering an oleaginous microorganism, to the engineered oleaginous microorganism obtained from such a process, and to a process for the production of a plasticising oil obtained from such an engineered oleaginous microorganism through cultivation in a culture medium containing biomass.
- Plasticising or process oils are used in industry, for example in the tyre industry. Plasticising oils are products of petrochemical derivation, like other products present in daily life such as fuels, plastics, synthetic fibres, solvents, fertilizers, fine chemicals, and ingredients for the formulation of drugs.
- oils are further classified according to the content of paraffinic, naphthenic and aromatic hydrocarbons.
- Plasticising oils include mild extraction solvent (MES) mineral oils, treated distillate aromatic extracts (TDAE), naphthenic oil (NAP), Residual Aromatic Extract (RAE) (adapted from SUCHIVA, Krisda “Introduction to Process oils.” Research and Development Centre for Thai Rubber Industry, Mahidol University).
- MES mild extraction solvent
- TDAE treated distillate aromatic extracts
- NAP naphthenic oil
- RAE Residual Aromatic Extract
- the new bioeconomy trends are based on the exploitation and enhancement of freshly synthesised biomass through sustainable processes with reduced environmental impact.
- This biomass represents the raw material of biorefinery, where this term means a production system capable of transforming a renewable substrate in times compatible with its use into a spectrum of products that can include bioenergy, biofuels and biomaterials, as is now possible starting from oil.
- biorefinery there are often bioprocesses, or transformations carried out by living organisms or enzymatic activities derived from them, accompanied by sustainable chemical processes.
- homogeneous and easily transformable substrates such as sugars in monomeric form or starches: in this case the biorefineries are defined as first-generation.
- second-generation biorefineries offer the possibility of using residual biomass as raw material, often of an inhomogeneous nature such as lignocellulose.
- the first-generation biorefinery constitutes an alternative source of plasticising oils, as in patents (W02012012133; US 8,969,454 B2; WO201 2085014; WO2013189917; WO2012085012) in which vegetable oils consisting of a mixture of triglycerides are used as extender (and/or plasticising) oils for tyre formulations.
- the raw material or starting substrate raises practical and ethical problems: in fact, the use of edible biomass overlaps and therefore competes with the agricultural and food chain, and its availability is subject to seasonality and climatic variability.
- microorganisms it is possible to use microorganisms to transform residual biomass into compounds of interest, including oils.
- yeasts constitute a valid platform for the development of bioprocesses, as many of them are genetically treatable and stable, easy to grow, safe for use (few yeasts are in fact known for their pathogenicity for humans, plants or animals, not subject to phage attack.
- yeast species are described as oleaginous, i.e. characterized by an oil content higher than 20% of the dry biomass. Furthermore, by suitably varying the growth conditions, their accumulation capacity rises to over 70% (as described in Thevenieau, F. et al., “Microorganisms as sources of oils.” Ocl 20.6 (2013): D603).
- oils produced by oil microorganisms can be used for various applications, such as (i) in the biodiesel industry, where microbial oils obtained from Rhodosporidium toruloides yeast and Chlorella spp. microalgae are used (as described in X. Zhao et al., “Effects of some inhibitors on the growth and lipid accumulation of oleaginous yeast Rhodosporidium toruloides and preparation of biodiesel by enzymatic transesterification of the lipid”, Bioprocess Biosyst. Eng., 35 (2012); Li, Yecong, et al. “Characterization of a microalga Chlorella sp.
- the Applicant has also developed an engineering process that allows an oleaginous yeast to be obtained which overexpresses a combination of endogenous genes encoding for enzymatic activities involved in the biosynthetic process of fatty acids, in particular (i) the enzyme delta-9 desaturase and (ii) the enzyme delta-12 desaturase.
- the Applicant has surprisingly observed that the oil obtained from the oleaginous yeast thus engineered had a particular enrichment in monounsatu rated fatty acids, unlike the expected enrichment in polyunsaturated fatty acids.
- a first aspect of the present invention consists in a process of engineering an oleaginous microorganism comprising the following steps:
- the microorganism is an oleaginous yeast of the group comprising the genera Cryptococcus, Lipomyces, Rhodosporidium, Rhodotorula, Trichosporon, Yarrowia.
- the microorganism belongs to strains of the species Cryptococcus curvatus, Lipomyces starkeyi, Rhodosporidium toruloides, Rhodotorula glutinis, Trichosporon fermentans, and Yarrowia lipolytica, more preferably Rhodosporidium toruloides and Lipomyces starkeyi.
- the microorganism is a microalgae of the group consisting of Chlorella ellipsoidea, Chlorella protothecoides, Chlorella vulgaris, Chlorella vulgaris, Dunaliella sp., Haematococcus pluvialis, Neochloris oleoabundans, Neochloris oleabundans, Pseudochlorococcum sp., Scenedesmus obliquus, Tetraselmis chui, Tetraselmis sp., Tetraselmis tetrathele, Chaetoceros calcitrans CS 178, Chaetoceros gracilis, Chaetoceros muelleri, Nitzschia of.
- the microorganism is selected from the group consisting of fungi and protists, such as for example Aspergullus terreus, Claviceps purpurea, Tolyposporium, Mortierella alpina, Mortierella isabellina, Schizochitrium limacynum.
- the gene encoding the enzyme delta-9 desaturase overexpressed in yeast is OLE1 of Lipomyces starkeyi having the sequence (SEQ ID NO: 1).
- the gene encoding the enzyme delta-12 desaturase overexpressed in yeast is FAD2 of Lipomyces starkeyi having the sequence (SEQ ID NO: 2).
- the oleaginous microorganism is Lipomyces starkeyi.
- the present invention also relates to the engineered oleaginous microorganism obtained with the process of the first aspect of the present invention, characterised by a carbon flow directed towards the synthesis of oil with a modified lipid profile compared to the wild oleaginous microorganism.
- the engineered oleaginous microorganism obtained with the process of the first aspect of the present invention is suitable for the production of oil starting from biomass.
- a third aspect of the present invention relates to a process for the production of a plasticising oil comprising a plasticising oil comprising the following steps of:
- the biomass comprises at least one source of organic carbon selected from the group consisting of crude glycerol, molasses, lignocellulose, sugar beet pulp, whey, starch residues, waste water, waste oils, glucose, xylose, arabinose, fructose, galactose, mannose, acetate, and/or a combination thereof.
- Figure 1 shows the fermentation profile of R. toruloides in a bioreactor with the main parameters related to obtaining the microbial oil 1 (OIL 1);
- Figure 2 shows the fermentation profile of L. starkeyi in a bioreactor with the main parameters relating to obtaining the microbial oil 2 (OIL 2);
- Figure 3 shows the map of the recombinant vector pLS01 bearing the expression cassette of the gene for resistance to nurseotricin (NrsR) deriving from plasmid pZs (Branduardi et al., “Biosynthesis of vitamin C by yeast leads to increased stress resistance.” PLoS One, 2, e1092, 2007);
- Figure 4 shows the map of the recombinant vector pLS02, derived from pLS01 and bearing a multiple cloning site (MCS);
- Figure 5 shows the map of the recombinant vector pLS02-OLE1, deriving from pLS02 and bearing (in the MCS) the expression cassette for the putative endogenous gene encoding for the enzyme delta-9 desaturase of L. starkeyi DSM70295;
- Figure 6 shows the fragment derived from pLS02-OLE1 which includes the expression cassette bearing the putative gene encoding for delta-9 desaturase (OLE1) and the gene for resistance to nurseotricin (NrsR): such a cassette is preferably integrative in the homologous ends;
- Figure 7 shows the map of the recombinant vector pLS03, bearing the expression cassette of the gene for resistance to hygromycin B (HygR) deriving from plasmid pZ4 (Branduardi et al., “The yeast Zygosaccharomyces bailii: a new host for heterologous protein production, secretion and for metabolic engineering applications.” FEMS yeast research 4.4-5 (2004): 493- 504);
- HygR hygromycin B
- Figure 8 shows the map of the recombinant vector pLS04, deriving from pLS03 and bearing a multiple cloning site (MCS);
- Figure 9 shows the map of the recombinant vector pLS04-FAD2, derived from pLS03 and bearing (in the MCS) the expression cassette for the endogenous gene encoding for the enzyme delta-12 desaturase deriving from L. starkeyi DSM70295;
- Figure 10 shows the fragment derived from pLS04-FAD2 which includes the expression cassette bearing the gene encoding for delta-12 desaturase (FAD2) and the gene for resistance to hygromycin B (FlygR): such a cassette is preferably integrative in the homologous ends;
- Figure 11 shows the image relating to the electrophoretic run carried out to confirm the successful integration of the expression cassette bearing the putative gene encoding for delta9 desaturase ( OLE1 ) and the gene for resistance to nurseotricin ( NrsR ) (Photo A), and to confirm the successful integration of the expression cassette bearing the gene coding for delta12 desaturase ( FAD2 ) and the gene for resistance to hygromycin B ( HygR ) (Photo B), where 1 represents the PCR negative control (water), 2 represents the integration negative control (DNA L. starkeyi), 3 represents the integration positive control pl_S04-OLE1 (Photo A) or pl_S04-FAD2 (Photo B), and 4 represents the engineered strain L. Starkeyi-OLE1 -FAD2;
- Figure 12 shows the graph representative of the number of copies of the OLE1 gene (Graph A) and of the FAD2 gene (Graph B) per cell, in the engineered strain, and in the wild control strain, to which unit value has been attributed;
- Figure 13 shows a representative graph of the expression levels of the putative gene encoding for the delta-9 desaturase enzyme activity ( OLE1 - Graph A) and of the gene encoding for the delta-12 desaturase enzyme activity ( FAD2 - Graph B) in the engineered strain, and in the wild control strain, to which unit value has been attributed;
- Figure 14 shows a graph representative of the trend over time of the growth and production of oily biomass of an engineered strain for the production of OIL 3, compared to the consumption of the supplied substrate (glycerol 100 g/L);
- Figure 15 shows the fermentation profile of engineered L. starkeyi in bioreactor, with the main parameters relating to obtaining the microbial oil (OIL 3), where the imbalance phase is shown in the graph with a dashed line;
- Figure 16 shows a histogram representative of the fatty acid composition related to OIL 3 compared to the composition of OIL 2.
- asterisks indicate statistical significance according to Student's t-test in the difference in lipid composition between OIL 2 and OIL 3 ( * p ⁇ 0.05, ** p ⁇ 0.005 and *** p ⁇ 0.0005);
- Figure 17 shows a graph representative of the number of copies of the OLE1 gene (Graph A) and of the FAD2 gene (Graph B) in the respective engineered strains compared to the wild control strain to which unit value has been attributed;
- Figure 18 shows a representative graph of the expression levels of the putative gene encoding for the delta-9 desaturase enzyme activity (OLE1 - Graph A) and of the gene encoding for the delta-12 desaturase enzyme activity (FAD2 - Graph B) in the respective engineered strains with respect to the wild control strain to which unit value has been attributed;
- Figure 19 shows a histogram representative of the fatty acid composition related to OIL 8 compared to the composition of OIL 3.
- asterisks indicate statistical significance according to Student's t-test in the difference in lipid composition between OIL 8 and OIL 3 ( * p ⁇ 0.05, ** p ⁇ 0.005 and *** p ⁇ 0.0005);
- Figure 20 shows a histogram representative of the fatty acid composition related to OIL 9 compared to the composition of OIL 3.
- asterisks indicate statistical significance according to Student's t-test in the difference in lipid composition between OIL 9 and OIL 3 ( * p ⁇ 0.05, ** p ⁇ 0.005 and *** p ⁇ 0.0005).
- biomass defines any substance of an organic nature that can regenerate in times compatible with its consumption, which can be used for the production of bioenergy, biofuels and biomaterials. This is in contrast to fossil biomass, whose regeneration times exceed those of consumption by many orders of magnitude.
- expression vector defines a DNA construct comprising a DNA sequence linked to a control sequence capable of leading to the expression of said DNA in a suitable host.
- the typical plasmid expression vector used has: a) an origin of replication which allows the actual replication of the plasmid so that in each cell of the selected host there are 1- 2 or tens of copies of the plasmid vector, or a DNA sequence that allows the integration of the plasmid vector into a chromosome of each cell of the selected host; b) a selection marker such that a cell correctly transformed with the plasmid vector can be selected; c) a DNA sequence comprising cleavage sites for restriction enzymes in order to be able to introduce exogenous DNA into the plasmid vector by a process called ligation.
- the coding sequence must be correctly and functionally connected to regulatory elements of the transcription, functioning in the selected expression host.
- transformation means that DNA, once introduced into the cell, can replicate outside chromosomes or as part of a chromosome.
- lipid bodies refers to the intracellular compartments present in animals, plants, fungi and even bacteria specialised for the accumulation of energy in the form of neutral lipids such as triglycerides and sterol esters.
- oleaginous microorganism refers to a microorganism capable of accumulating at least 20% of lipids with respect to its dry weight.
- delta-9 desaturase refers to a polypeptide belonging to the family of enzymes EC 1.14.19.1 which catalyses the introduction of a double bond in the delta-9 position of the fatty acid chain. Such a reaction has palmitic and/or stearic acid as its predominant substrate, giving rise to palmitoleic and/or oleic acid, respectively.
- delta-12 desaturase refers to a polypeptide belonging to the family of enzymes EC 1.14.19.6 which catalyses the introduction of a double bond in the delta-12 position of the fatty acid chain. Such a reaction has oleic acid as its predominant substrate, giving rise to linoleic acid.
- OIL 1 and OIL 2 The microbial oils with plasticising action (OIL 1 and OIL 2) were produced according to the procedures described below.
- Table 1 shows the fatty acid composition relating to OIL 1 and OIL 2, expressed as a percentage weight by weight (% w/w) at the final time.
- the cells of the oleaginous yeast strain R. toruloides DSM4444 were pre- inoculated into the medium from the following composition: 1 g of yeast extract, 1.31 g (NH bO ⁇ 0.95 Na 2 HP04, 2.7 g KH2PO4, 0.2 g MgS0 4 * 7H2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2H2O, 0.55 g FeSC>4 * 7H2O, 0.52 g citric acid, 0.10 g ZnSC>4 * 7H2O, 0.076 g MnSC>4 * H2O, 100 microlitres of H2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon.
- This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts.
- the pre inoculation was carried out in 200 ml_ of medium in 1 L flasks placed at 25 °C on an orbital shaker at 220 rpm. After 72 hours of growth, the cells were inoculated in a 2L bioreactor at an initial DO660 of approximately 1.
- the operating volume of medium corresponds to lOOOmL in the presence of about 40 g/L of glycerol.
- the imbalancing phase began, where crude glycerol was added to the medium to reach a final concentration of about 50 g/L.
- the C:N molar ratio therefore switches to the value of about 30:1 , causing a metabolic variation towards the accumulation of microbial oils in the so-called lipid bodies at the expense of cell divisions, which cannot be performed due to the scarcity of the nitrogen source.
- the fermentation parameters require the bioreactor to maintain a constant temperature of 25 °C; an amount of dissolved oxygen greater than 25% with an air flow of 1 vvm (volume of air per volume of culture medium); the pH is maintained at 5.5 with the addition, if necessary, of NaOH 4M and H3PO4 at 25% (v/v); stirring is dependent on the percentage of oxygen dissolved in the medium.
- the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids.
- HCI 2M acid lysis
- the chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring.
- Figure 1 shows the fermentation profile of R. toruloides with respect to the biomass trend over time (symbol ⁇ ) and the corresponding substrate consumption (symbol A), where the imbalance phase is shown in the graph with a dashed line, the line with the symbol A represents the trend of the glycerol concentration, and the line with the symbol ⁇ represents the trend of the biomass.
- the cells of the oleaginous yeast strain Lipomyces starkeyi DSM70295 were pre-inoculated into the medium from the following composition: 1 g of yeast extract, 1.31 g (NH bO ⁇ 0.95 Na2HP04, 2.7 g KH2PO4, 0.2 g MgSC>4 * 7H2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2H2O, 0.55 g FeSC>4 * 7FI2O, 0.52 g citric acid, 0.10 g ZnSC>4 * 7FI2O, 0.076 g MnSC>4 * FI2O, 100 microlitres of FI2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon.
- This concentration allows a C:N molar ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts.
- the pre-inoculation was carried out in 200 mL of medium in 1 L flasks placed at 25 °C on an orbital shaker at 220 rpm.
- the cells were inoculated in a 2L bioreactor at an initial DO660 of 3.
- the operating volume of medium corresponds to 1000 mL in the presence of about 60 g/L of glycerol.
- the imbalancing phase began, where crude glycerol was added to the medium to reach a final concentration of 60 g/L.
- the C:N molar ratio therefore switches to the value of about 40:1 , causing a metabolic variation towards the accumulation of microbial oils in the so-called lipid bodies at the expense of cell divisions, which cannot be performed due to the scarcity of the nitrogen source.
- the fermentation parameters require the bioreactor to maintain a constant temperature of 25 °C; an amount of dissolved oxygen greater than 25% with an air flow of 1 vvm (volume of air per volume of culture medium); the pH is maintained at 5.5 with the addition, if necessary, of NaOH 4M and H3PO4 at 25% (v/v); stirring is dependent on the percentage of oxygen dissolved in the medium.
- the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids.
- HCI 2M acid lysis
- the chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring.
- Figure 2 shows the fermentation profile of L. starkeyi with respect to the biomass trend over time (symbol ⁇ ) and the corresponding substrate consumption (symbol A), where the imbalance phase is shown in the graph with a dashed line, the line with the symbol A represents the trend of the glycerol concentration, and the line with the symbol ⁇ represents the trend of the biomass.
- This example describes the procedure for preparing the expression cassette containing the putative sequence encoding for the delta9 desaturase activity under the control of the pTDH3 promoter and tPGK1 terminator together with the resistance cassette to nurseotricin NsrR.
- the sequences for the pURA3 promoter and tGAL1 terminator of L. starkeyi were amplified by PCR using as a template the genomic DNA of L. starkeyi DSM70295 and specific oligonucleotides (SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO:5; SEQ ID NO:6).
- the NAT gene encoding for the resistance to nurseotricin was amplified by PCR using as a template the plasmid pZs and specific oligonucleotides (SEQ ID NO: 7; SEQ ID NO: 8).
- the program used for both amplifications is as follows: after 30 seconds of denaturation at 98 °C, 35 cycles (10 second denaturation at 98 °C, 30 second pairing at 64 °C and 30 seconds elongation at 72 °C ), followed by a final elongation of 2 minutes at 72 °C.
- the PCR products were loaded onto 0.8% agarose gel and the fragments of interest were recovered by excision and purified with the NucleoSpin Gel and PCR clean-up kit (MACHEREY- NAGEL GmbH & Co. KG).
- the NrsR gene amplified by plasmid pZs, and pURA3 and t GAL1, amplified by the genomic DNA of L.
- pl_S01 -L/rsft was purified on a column using the NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG) and sequenced using the specific oligonucleotides (SEQ ID NO: 9; SEQ ID NO: 10).
- Figure 3 shows the recombinant vector pl_S01 -L/rsft.
- the pLS01 vector was subjected to preparative digestion with the restriction enzyme EcoRV for linearization.
- the vector was recovered by removal from agarose gel and then purified with NucleoSpin Gel and PCR clean-up and quantified with Nanodrop [Euroclone (Spa)].
- the constitutive and strong promoter of the endogenous gene of L. starkeyi TDH3 and the terminator of the endogenous gene of L. starkeyi PGK1 were inserted in the linearized pl_S01 plasmid: these sequences were amplified by PCR using as model the genomic DNA of L.
- the correct insertion of the p TDH3, tPGK1 fragments inside the pl_S01 -L/rsft plasmid was verified through the analytical digestions carried out with Pstl and Pmll.
- the vector pLS02 was purified on a column using NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG) and sequenced using the specific oligonucleotides (SEQ ID NO: 9; SEQ ID NO: 15).
- Figure 4 shows the vector pLS02.
- the sequence encoding for the enzyme delta-9 desaturase was amplified by PCR using the genomic DNA of L. starkeyi DSM70295 as a template and specially designed oligonucleotides (SEQ ID NO: 16; SEQ ID NO:17).
- the program used for amplification is as follows: after 30 seconds of denaturation at 98 °C, 30 cycles (10 second denaturation at 98 °C, 30 second pairing at 72 °C and 60 second elongation at 72 °C ), followed by a final elongation of 2 minutes at 72 °C.
- the PCR product and the target vector pLS02-MCS were digested with the restriction enzyme Spel and their ligation led to the obtainment of the recombinant expression vector pLS02 -OLE1.
- the vector pLS02 -OLE1 was removed from agarose gel and purified on a column using NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG), quantified and sequenced using the specific oligonucleotides (SEQ ID NO: 15; SEQ ID NO: 14).
- Figure 5 shows the vector pl_S02 -OLE1.
- the pl_S02 vector was digested with the EcoRI-HF restriction enzyme.
- the fragment corresponding to the expression cassette (4556 bp) was recovered by removal from 0.8% agarose gel and purified with NucleoSpin Gel and PCR clean-up.
- Figure 6 shows the expression cassette for the sequence encoding for the delta9 desaturase activity ( OLE1 ).
- This example describes the procedure for preparing the expression cassette containing the sequence encoding for the delta12 desaturase activity under the control of the pTDH3 promoter and tPGK1 terminator together with the resistance cassette to hygromycin HygR.
- the HygR gene for resistance to hygromycin B (4-O-kinase) was amplified by PCR using as a template the plasmid pZ4 and specific oligonucleotides (SEQ ID NO: 18; SEQ ID NO: 19).
- the program used for the amplification is as follows: after 30 seconds of denaturation at 98 °C, 35 cycles (10 second denaturation at 98 °C, 30 second pairing at 68°C and 30 second elongation at 72 °C ), followed by a final elongation of 2 minutes at 72 °C.
- the PCR product was loaded onto 0.8% agarose gel and the fragments of interest were recovered by excision and purified with the NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG).
- the hph gene amplified by the plasmid pZ4, was inserted into the pStblue-1 vector by cloning using the Gibson assembly cloning kit (New England Biolab, NEB). Once the plasmid extraction from E. coli was performed, visualized by electrophoretic run on 0.8% agarose gel, the correct insertion of the hph fragment in the pSTBIue plasmid was verified through analytical digestions tests carried out with the restriction enzymes Hhel and Hindi.
- the vector named pLS03 -HygR was purified on the column using the kit described above and sequenced using the specific oligonucleotides (SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:18).
- Figure 7 shows the recombinant vector pLS03.
- the target vector pLS02 was digested with the restriction enzyme Nhel to obtain the linearized pl_S02 vector and remove the nurseotricin resistance gene ( NrsR ). Similarly, using the same restriction enzyme Nhel, the pl_S03 vector was digested to obtain the HygR gene, which confers resistance to the hygromycin-B antibiotic.
- HygR gene and the pl_S02 vector were recovered by removal from agarose gel and then purified with NucleoSpin Gel and PCR clean-up and quantified with Nanodrop [Euroclone (Spa)]. The ligation was then carried out which led to the obtainment of the recombinant expression vector pl_S04 bearing resistance to the antibiotic hygromycin B. The correct insertion of the HygR fragment inside the pl_S02 plasmid was verified through the analytical digestion carried out with Sacll.
- Figure 8 shows the recombinant vector pl_S04.
- the sequence encoding for the enzyme delta-12 desaturase was amplified by PCR using the genomic DNA of L. starkeyi DSM70295 as a template and specific oligonucleotides (SEQ ID NO: 20; SEQ ID NO:21).
- the program used for the amplification is as follows: after 30 seconds of denaturation at 98 °C, 10 cycles (10 second denaturation at 98 °C, 30 second pairing at 59 °C and 40 second elongation at 72 °C ), 25 cycles (10 second denaturation at 98 °C, 30 second pairing at 64 °C and 40 second elongation at 72 °C), followed by a final 2 minute elongation at 72 °C.
- the target vector pLS04- MCS was digested with the restriction enzyme EcoRV-HF, and ligated to the PCR product leading to the obtainment of the recombinant expression vector pLS04-F4D2.
- the vector pLS04-F4D2 was purified on a column using NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG) and sequenced using the specific oligonucleotides (SEQ ID NO: 15; SEQ ID NO: 14).
- Figure 9 shows the vector pl_S04-F4D2.
- the pl_S04-F4D2 vector was digested with the restriction enzyme Xhol.
- the fragment corresponding to the expression cassette (4765 bp) was recovered by removal from 0.8% agarose gel and purified with NucleoSpin Gel and PCR clean-up.
- Figure 10 shows the expression cassette for the sequence encoding for the delta12 desaturase activity ( FAD2 ).
- the laboratory strain of L. starkeyi DSM70295 was transformed using two expression cassettes of which (i) one containing the putative sequence encoding for the delta9 desaturase activity under the control of the pTDH3 promoter and t PGK1 terminator together with the resistance cassette to nurseotricin NsrR, described in example 2, and (ii) one containing the sequence encoding for the delta12 desaturase activity under the control of the p TDH3 promoter and the t PGK1 terminator together with the hygromycin resistance cassette HygR, described in example 3.
- the messengers for delta-9 desaturase and delta-12 desaturase in the recombinant strain L. starkeyi-OLE1-FAD2 and in the wild strain are quantified from the cDNA obtained by retro-transcription of the total RNA ( Figure 13).
- the cells were pre-inoculated in 5 ml of the medium containing: Glucose 25%, xylose 25%, 1 g of yeast extract, 1.31 g (NH bO ⁇ 0.95 Na2HPC>4, 2.7 g KH2PO4, 0.2 g MgSC * 7H2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2H2O, 0.55 g FeSC>4 * 7FI2O, 0.52 g citric acid, 0.10 g ZnS0 4 * 7H20, 0.076 g MnS0 4 * H2O, 100 microlitres of FI2SO4 18 M, per litre of solution) for 24 h.
- RNA extraction was performed on a sample of cells in the exponential phase, using the ZR Fungal/Bacterial RNA Miniprep kit (Zymoresearch/The epigenitics company). The extraction was then controlled with electrophoretic run on 1.5% agarose gel. The cDNA was obtained using the iScript cDNA Synthesis (BIORAD) kit. Real-time PCR was performed using specific oligonucleotides (SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27) and actin as internal control (SEQ ID NO: 28; SEQ ID NO: 29).
- the cells of the oleaginous yeast strain L. starkeyi-OLE1-FAD2, engineered for the production of modified lipid oil (OIL 3) were pre-inoculated into the medium with the following composition: 1 g yeast extract, 1.31 g (NH ) 2 S04, 0.95 Na 2 HP0 4 , 2.7 g KH2PO4, 0.2 g MgS0 4 * 7H 0, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2H2O, 0.55 g FeS0 4 * 7H 2 0, 0.52 g citric acid, 0.10 g ZnS0 4 * 7H 2 0, 0.076 g MnS04 * FI2O, 100 microlitres of FI2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon.
- glycerol 15 g/L as a source of energy and carbon.
- This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts.
- the pre-inoculation was carried out in 100 mL of medium in 500L flasks placed at 25 °C on an orbital shaker at 220 rpm. After 72 hours of growth, the cells were inoculated at an optical density of 3 (OD 660 nm) in 50 mL of medium, the same used for pre-inoculation in the presence of about 100 g/L of glycerol, in 250 imL flasks placed at 25 °C on an orbital shaker at 220 rpm. Cell growth was monitored by measuring OD at 660 nm at regular time intervals. The extracellular concentration of glycerol was determined by HPLC using H2SO4 0.01 M as mobile phase and a Rezex ROA-Organic (Phenomenex) column.
- the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids.
- HCI 2M acid lysis
- the chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring.
- Figure 14 shows the fermentation profile of the L. starkeyi-OLE1-FAD2 strain with respect to the biomass trend over time and the corresponding substrate consumption.
- Table 2 shows the fatty acid composition relating to OIL 3 compared with the composition of OIL 1 and 2 and of some vegetable oils, in particular castor oil (OIL 4), sunflower oil AP- 75 ® (Cargill) (OIL 5), sunflower oil AP-88 ® (Cargill) (OIL 6). TABLE 2
- the following table 3 summarises the characterisation of the oils of Table 2 and of a mineral oil MES (TUDALEN 4226, H&R Group) (OIL 7) as a functional reference carried out using Differential Scanning Calorimetry (DSC), starting from a temperature of -140 °C to +60 °C to establish the melting temperature and the glass transition temperature.
- the iodine number was determined using the ISO 3961 method, which involves treating the oil with an excess Wijs solution. Wijs solution contains iodine monochloride dissolved in acetic acid. The iodine monochloride reacts with the unsaturated part of the oil and the unreacted iodine is released as iodine by adding potassium iodide. The released iodine is determined by titration with sodium thiosulfate.
- the cells of the oleaginous yeast strain L. starkeyi-OLE1-FAD2, engineered for the production of modified lipid oil (OIL 3) were pre-inoculated into the medium with the following composition: 1 g of yeast extract, 1.31 g (NH )2S04, 0.95 Na 2 HP04, 2.7 g KH2PO4, 0.2 g MgS0 4 * 7H 0, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCL * 2H2O, 0.55 g FeS0 4 * 7H 2 0, 0.52 g citric acid, 0.10 g ZnS0 4 * 7H 2 0, 0.076 g MnS04 * H2O, 100 microlitres of H2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon.
- glycerol 15 g/L as a source of energy and carbon.
- This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts.
- the pre-inoculation was carried out in 200 mL of medium in 1000L flasks placed at 25 °C on an orbital shaker at 220 rpm. After about 48 hours of growth, the cells were inoculated in a 10L bioreactor at an initial DO660 of 0.2.
- the operating volume of medium corresponds to 5000mL in the presence of about 25g/L of glycerol.
- the operating volume of medium used in the bioreactor is 5000mL.
- the imbalancing phase began, where crude glycerol was added to the medium to reach a final concentration of about 80 g/L.
- the C:N molar ratio therefore switches to the value of about 50:1 , causing a metabolic variation towards the accumulation of microbial oils in the so-called lipid bodies at the expense of cell divisions, which cannot be performed due to the scarcity of the nitrogen source.
- the fermentation parameters require the bioreactor to maintain a constant temperature of 25 °C; an amount of dissolved oxygen greater than 25% with an air flow of 1 vvm (volume of air per volume of culture medium); the pH is maintained at 5.5 with the addition, if necessary, of NaOH 4M and H3PO4 at 25% (v/v); stirring is dependent on the percentage of oxygen dissolved in the medium.
- the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids.
- HCI 2M acid lysis
- the chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring.
- Figure 15 shows the fermentation profile of L. starkeyi-OLE1-FAD2 with respect to the biomass trend over time and the corresponding substrate consumption.
- the cells of the oleaginous yeast strain L. starkeyi-OLE1-FAD2, engineered for the production of modified lipid oils (OIL 3) were pre inoculated into the medium with the following composition: 1 g yeast extract, 1.31 g (NH )2S04, 0.95 Na 2 HP04, 2.7 g KH2PO4, 0.2 g MgS0 4 * 7H 0, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCL * 2H2O, 0.55 g FeS04 * 7H2O, 0.52 g citric acid, 0.10 g ZnS0 4 * 7H2O, 0.076 g MnS04 * H2O, 100 microlitres of H2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon.
- glycerol 15 g/L as a source of energy and carbon.
- This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts.
- the pre-inoculation was carried out in 100 mL of medium in 500L flasks placed at 25 °C on an orbital shaker at 220 rpm. After 72 hours of growth, the cells were inoculated at an optical density of 3 (OD 660 nm) in 50 mL 20 of medium, the same used for pre-inoculation in the presence of about 100 g/L of glycerol, in 250 mL flasks placed at 25 °C on an orbital shaker at 220 rpm. Cell growth was monitored by measuring OD at 660 nm at regular time intervals.
- the extracellular concentration of glycerol was determined by HPLC using H2SO4 0.01 M as mobile phase and a Rezex ROA-Organic (Phenomenex) column. After 240 hours from inoculation, the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids.
- HCI 2M acid lysis
- the chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring.
- Figure 16 shows the composition of fatty acids relating to OIL 3 compared to the composition of OIL 2.
- the laboratory strain of L. starkeyi DSM70295 was transformed using the expression cassette containing the putative sequence encoding for the delta9 desaturase activity under the control of the pTDH3 promoter and tPGK1 terminator together with the nurseotricin NsrR resistance cassette, described in Example 2.
- the laboratory strain of L. starkeyi DSM70295 was transformed using the expression cassette containing the sequence encoding for the delta12 desaturase activity under the control of the pTDH3 promoter and tPGK1 terminator together with the hygromycin HygR resistance cassette, described in Example 3.
- the messengers for delta-9 desaturase and delta-12 desaturase in the recombinant strains L. starkeyi- OLE1 , L. starkeyi- FAD2 and in the wild strain are quantified from the cDNA obtained by retro-transcription of the total RNA ( Figure 18).
- the cells were pre-inoculated in 5 ml of the medium containing: Glucose 25%, xylose 25%, 1 g of yeast extract, 1.31 g (NFl4)2S04, 0.95 Na2FIP04, 2.7 g KFI2PO4, 0.2 g MgS04 * 7FI2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2FI2O, 0.55 g FeS04 * 7H2O, 0.52 g citric acid, 0.10 g ZnS0 4 * 7H20, 0.076 g MnS0 4 * H2O, 100 microlitres of FI2SO4 18 M, per litre of solution) for 24 h.
- RNA extraction was performed on a sample of cells in the exponential phase, using the ZR Fungal/Bacterial RNA Miniprep kit (Zymoresearch/The epigenitics company). The extraction was then controlled with electrophoretic run on 1.5% agarose gel. The cDNA was obtained using the iScript cDNA Synthesis (BIORAD) kit. Real-time PCR was performed using specific oligonucleotides (SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27) and actin as internal control (SEQ ID NO: 28; SEQ ID NO: 29).
- EXAMPLE 14 Production kinetics of oil in flasks of the oleaginous yeasts L. starkevi - OLE1 and L. starkevi -FAD2, engineered for the modification of the lipid profile of the oil with respect to the wild strain.
- the cells of the oleaginous yeast strains L. starkeyi-O El and L. starkeyi- FAD2, engineered for the production of oils with a modified lipid profile (OIL 8 and OIL 9) were pre-inoculated in the medium with the following composition: 1 g yeast extract, 1.31 g (NH bO ⁇ 0.95 Na2HP04, 2.7 g KH2PO4, 0.2 g MgS04 * 7H2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCL * 2H2O, 0.55 g FeS04 * 7H2O, 0.52 g citric acid, 0.10 g ZnS04 * 7H2O, 0.076 g MnS04 * H2O, 100 microlitres of H2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon.
- This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts.
- the pre-inoculation was carried out in 100 mL of medium in 500L flasks placed at 25 °C on an orbital shaker at 220 rpm. After 72 hours of growth, the cells were inoculated at an optical density of 3 (OD 660 nm) in 50 mL 20 of medium, the same used for pre-inoculation in the presence of about 100 g/L of glycerol, in 250 mL flasks placed at 25 °C on an orbital shaker at 220 rpm. Cell growth was monitored by measuring OD at 660 nm at regular time intervals.
- the extracellular concentration of glycerol was determined by HPLC using H2SO40.01 M as mobile phase and a Rezex ROA-Organic (Phenomenex) column. After 240 hours from inoculation, the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids.
- HCI 2M acid lysis
- the chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a process of engineering an oleaginous microorganism, to the engineered oleaginous microorganism obtained from such a process, and to the process for the production of a plasticising oil obtained from such an engineered oleaginous microorganism through cultivation in a culture medium containing biomass.
Description
TITLE
“PROCESS OF ENGINEERING AN OLEAGINOUS MICROORGANISM”
DESCRIPTION FIELD OF THE INVENTION
The present invention relates to a process of engineering an oleaginous microorganism, to the engineered oleaginous microorganism obtained from such a process, and to a process for the production of a plasticising oil obtained from such an engineered oleaginous microorganism through cultivation in a culture medium containing biomass.
PRIOR ART
Plasticising or process oils are used in industry, for example in the tyre industry. Plasticising oils are products of petrochemical derivation, like other products present in daily life such as fuels, plastics, synthetic fibres, solvents, fertilizers, fine chemicals, and ingredients for the formulation of drugs.
These oils are further classified according to the content of paraffinic, naphthenic and aromatic hydrocarbons.
Plasticising oils include mild extraction solvent (MES) mineral oils, treated distillate aromatic extracts (TDAE), naphthenic oil (NAP), Residual Aromatic Extract (RAE) (adapted from SUCHIVA, Krisda “Introduction to Process oils.” Research and Development Centre for Thai Rubber Industry, Mahidol University).
The problems associated with mineral oils are linked to the non- renewability of the raw material (in times compatible with its consumption).
The new bioeconomy trends are based on the exploitation and enhancement of freshly synthesised biomass through sustainable processes with reduced environmental impact.
This biomass represents the raw material of biorefinery, where this term means a production system capable of transforming a renewable substrate in times compatible with its use into a spectrum of products that can include bioenergy, biofuels and biomaterials, as is now possible starting from oil. At the heart of biorefinery there are often bioprocesses, or transformations carried out by living organisms or enzymatic activities derived from them, accompanied by sustainable chemical processes. In this technology it is
possible to use homogeneous and easily transformable substrates, such as sugars in monomeric form or starches: in this case the biorefineries are defined as first-generation. Alternatively, second-generation biorefineries offer the possibility of using residual biomass as raw material, often of an inhomogeneous nature such as lignocellulose.
The first-generation biorefinery constitutes an alternative source of plasticising oils, as in patents (W02012012133; US 8,969,454 B2; WO201 2085014; WO2013189917; WO2012085012) in which vegetable oils consisting of a mixture of triglycerides are used as extender (and/or plasticising) oils for tyre formulations. As previously introduced, the raw material or starting substrate raises practical and ethical problems: in fact, the use of edible biomass overlaps and therefore competes with the agricultural and food chain, and its availability is subject to seasonality and climatic variability.
It is possible to use microorganisms to transform residual biomass into compounds of interest, including oils. Among microorganisms, yeasts constitute a valid platform for the development of bioprocesses, as many of them are genetically treatable and stable, easy to grow, safe for use (few yeasts are in fact known for their pathogenicity for humans, plants or animals, not subject to phage attack.
In particular, various yeast species are described as oleaginous, i.e. characterized by an oil content higher than 20% of the dry biomass. Furthermore, by suitably varying the growth conditions, their accumulation capacity rises to over 70% (as described in Thevenieau, F. et al., “Microorganisms as sources of oils.” Ocl 20.6 (2013): D603).
By way of non-exhaustive description, oils produced by oil microorganisms can be used for various applications, such as (i) in the biodiesel industry, where microbial oils obtained from Rhodosporidium toruloides yeast and Chlorella spp. microalgae are used (as described in X. Zhao et al., “Effects of some inhibitors on the growth and lipid accumulation of oleaginous yeast Rhodosporidium toruloides and preparation of biodiesel by enzymatic transesterification of the lipid”, Bioprocess Biosyst. Eng., 35 (2012); Li, Yecong, et al. “Characterization of a microalga Chlorella sp. well adapted to
highly concentrated municipal wastewater for nutrient removal and biodiesel production.” Bioresource technology 102.8 (2011): 5138-5144) and (ii) in the biofuel industry and in the food industry as an alternative source of polyunsaturated fatty acids, where oils produced by the oleaginous yeast Lipomyces starkeyi are used (as described in Angerbauer, Christoph, et al. “Conversion of sewage sludge into lipids by Lipomyces starkeyi for biodiesel production.” Bioresource technology 99.8 (2008): 3051-3056; and in Blomqvist, Johanna, et al. Oleaginous yeast as a component in fish feed.” Scientific reports 8.1 (2018): 15945).
In second-generation biorefineries, residual biomass deriving from other industrial processes and/or biomass not in competition with the food chain are therefore used (as described in Naik, S. N, et al. “Production of first and second generation biofuels: a comprehensive review.” Renewable and sustainable energy reviews 14.2 (2010): 578-597; and in Stichnothe, H., et al. “Development of Second-Generation Biorefineries.” Developing the Global Bioeconomy. 2016. 11-40).
Furthermore, further examples of applications obtained after engineering of oleaginous microorganisms are reported in the literature: the yeast Criptococcus curvatus, mutated due to the partial block of the delta-9 desaturase enzymatic activity, allows oils with a composition similar to cocoa butter to be obtained (as described in Hassan, Mainul, et al. “Production of cocoa butter equivalents from prickly-pear juice fermentation by an unsaturated fatty acid auxotroph of Cryptococcus curvatus grown in batch culture.” Process Biochemistry 30.7 (1995): 629-634); and wild and mutated strains of R. toruloides have been used as producers of oils for the production of biodiesel and oleochemicals (as described in WO2016/185073 and Koutinas, Apostolis A., et al. “Design and techno-economic evaluation of microbial oil production as a renewable resource for biodiesel and oleochemical production.” Fuel 116 (2014): 566-577).
SUMMARY OF THE INVENTION
In view of what is known in the art, the Applicant has also developed an engineering process that allows an oleaginous yeast to be obtained which overexpresses a combination of endogenous genes encoding for enzymatic
activities involved in the biosynthetic process of fatty acids, in particular (i) the enzyme delta-9 desaturase and (ii) the enzyme delta-12 desaturase.
The Applicant has surprisingly observed that the oil obtained from the oleaginous yeast thus engineered had a particular enrichment in monounsatu rated fatty acids, unlike the expected enrichment in polyunsaturated fatty acids.
Therefore, a first aspect of the present invention consists in a process of engineering an oleaginous microorganism comprising the following steps:
(a) providing an oleaginous microorganism;
(b) inserting the gene encoding the enzyme delta-9 desaturase into the oleaginous microorganism;
(c) inserting the gene encoding the enzyme delta-12 desaturase into the oleaginous microorganism;
(d) selecting the resulting engineered microorganism.
According to an embodiment of the first aspect of the present invention, the microorganism is an oleaginous yeast of the group comprising the genera Cryptococcus, Lipomyces, Rhodosporidium, Rhodotorula, Trichosporon, Yarrowia.
According to a preferred embodiment of the first aspect of the present invention, the microorganism belongs to strains of the species Cryptococcus curvatus, Lipomyces starkeyi, Rhodosporidium toruloides, Rhodotorula glutinis, Trichosporon fermentans, and Yarrowia lipolytica, more preferably Rhodosporidium toruloides and Lipomyces starkeyi.
According to an alternative embodiment of the first aspect of the present invention, the microorganism is a microalgae of the group consisting of Chlorella ellipsoidea, Chlorella protothecoides, Chlorella vulgaris, Chlorella vulgaris, Dunaliella sp., Haematococcus pluvialis, Neochloris oleoabundans, Neochloris oleabundans, Pseudochlorococcum sp., Scenedesmus obliquus, Tetraselmis chui, Tetraselmis sp., Tetraselmis tetrathele, Chaetoceros calcitrans CS 178, Chaetoceros gracilis, Chaetoceros muelleri, Nitzschia of. pusilla YSR02, Phaeodactylum tricornutum F&M-M40, Skeletonema sp. CS 252, Thalassiosira pseudonana CS 173 Crypthecodinium cohnii, Isochrysis sp., Isochrysis sp., Isochrysis zhangjiangensis, Nannochloropsis oculate,
Nannochloropsis oculata NCTU-3, Nannochloropsis sp., Pavlova salina CS 49, Rhodomonas sp., Thalassiosira weiss f log ii.
According to an alternative embodiment of the first aspect of the present invention, the microorganism is selected from the group consisting of fungi and protists, such as for example Aspergullus terreus, Claviceps purpurea, Tolyposporium, Mortierella alpina, Mortierella isabellina, Schizochitrium limacynum.
According to a preferred embodiment of the first aspect of the present invention, the gene encoding the enzyme delta-9 desaturase overexpressed in yeast is OLE1 of Lipomyces starkeyi having the sequence (SEQ ID NO: 1).
According to a preferred embodiment of the first aspect of the present invention, the gene encoding the enzyme delta-12 desaturase overexpressed in yeast is FAD2 of Lipomyces starkeyi having the sequence (SEQ ID NO: 2).
According to a preferred embodiment of the first aspect of the present invention, the oleaginous microorganism is Lipomyces starkeyi.
In a second aspect thereof, the present invention also relates to the engineered oleaginous microorganism obtained with the process of the first aspect of the present invention, characterised by a carbon flow directed towards the synthesis of oil with a modified lipid profile compared to the wild oleaginous microorganism.
The engineered oleaginous microorganism obtained with the process of the first aspect of the present invention is suitable for the production of oil starting from biomass.
Therefore, a third aspect of the present invention relates to a process for the production of a plasticising oil comprising a plasticising oil comprising the following steps of:
(a) cultivation of engineered oleaginous microorganisms obtained by the process of the first aspect of the present invention in a culture medium comprising biomass containing a carbon to nitrogen molar ratio between 5 and 20;
(b) imbalance by variation of the carbon to nitrogen molar ratio at values equal to or greater than 30, preferably between 30 and 100;
(c) separation of engineered oleaginous microorganisms from the culture
medium; and
(d) extraction of the oil from oleaginous microorganisms.
According to an embodiment of the third aspect of the present invention, the biomass comprises at least one source of organic carbon selected from the group consisting of crude glycerol, molasses, lignocellulose, sugar beet pulp, whey, starch residues, waste water, waste oils, glucose, xylose, arabinose, fructose, galactose, mannose, acetate, and/or a combination thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention will now be described, for non-limiting illustrative purposes, according to preferred embodiments thereof, with particular reference to the accompanying figures, in which:
Figure 1 shows the fermentation profile of R. toruloides in a bioreactor with the main parameters related to obtaining the microbial oil 1 (OIL 1);
Figure 2 shows the fermentation profile of L. starkeyi in a bioreactor with the main parameters relating to obtaining the microbial oil 2 (OIL 2);
Figure 3 shows the map of the recombinant vector pLS01 bearing the expression cassette of the gene for resistance to nurseotricin (NrsR) deriving from plasmid pZs (Branduardi et al., “Biosynthesis of vitamin C by yeast leads to increased stress resistance.” PLoS One, 2, e1092, 2007);
Figure 4 shows the map of the recombinant vector pLS02, derived from pLS01 and bearing a multiple cloning site (MCS);
Figure 5 shows the map of the recombinant vector pLS02-OLE1, deriving from pLS02 and bearing (in the MCS) the expression cassette for the putative endogenous gene encoding for the enzyme delta-9 desaturase of L. starkeyi DSM70295;
Figure 6 shows the fragment derived from pLS02-OLE1 which includes the expression cassette bearing the putative gene encoding for delta-9 desaturase (OLE1) and the gene for resistance to nurseotricin (NrsR): such a cassette is preferably integrative in the homologous ends;
Figure 7 shows the map of the recombinant vector pLS03, bearing the expression cassette of the gene for resistance to hygromycin B (HygR) deriving from plasmid pZ4 (Branduardi et al., “The yeast Zygosaccharomyces
bailii: a new host for heterologous protein production, secretion and for metabolic engineering applications.” FEMS yeast research 4.4-5 (2004): 493- 504);
Figure 8 shows the map of the recombinant vector pLS04, deriving from pLS03 and bearing a multiple cloning site (MCS);
Figure 9 shows the map of the recombinant vector pLS04-FAD2, derived from pLS03 and bearing (in the MCS) the expression cassette for the endogenous gene encoding for the enzyme delta-12 desaturase deriving from L. starkeyi DSM70295;
Figure 10 shows the fragment derived from pLS04-FAD2 which includes the expression cassette bearing the gene encoding for delta-12 desaturase (FAD2) and the gene for resistance to hygromycin B (FlygR): such a cassette is preferably integrative in the homologous ends;
Figure 11 shows the image relating to the electrophoretic run carried out to confirm the successful integration of the expression cassette bearing the putative gene encoding for delta9 desaturase ( OLE1 ) and the gene for resistance to nurseotricin ( NrsR ) (Photo A), and to confirm the successful integration of the expression cassette bearing the gene coding for delta12 desaturase ( FAD2 ) and the gene for resistance to hygromycin B ( HygR ) (Photo B), where 1 represents the PCR negative control (water), 2 represents the integration negative control (DNA L. starkeyi), 3 represents the integration positive control pl_S04-OLE1 (Photo A) or pl_S04-FAD2 (Photo B), and 4 represents the engineered strain L. Starkeyi-OLE1 -FAD2;
Figure 12 shows the graph representative of the number of copies of the OLE1 gene (Graph A) and of the FAD2 gene (Graph B) per cell, in the engineered strain, and in the wild control strain, to which unit value has been attributed;
Figure 13 shows a representative graph of the expression levels of the putative gene encoding for the delta-9 desaturase enzyme activity ( OLE1 - Graph A) and of the gene encoding for the delta-12 desaturase enzyme activity ( FAD2 - Graph B) in the engineered strain, and in the wild control strain, to which unit value has been attributed;
Figure 14 shows a graph representative of the trend over time of the
growth and production of oily biomass of an engineered strain for the production of OIL 3, compared to the consumption of the supplied substrate (glycerol 100 g/L);
Figure 15 shows the fermentation profile of engineered L. starkeyi in bioreactor, with the main parameters relating to obtaining the microbial oil (OIL 3), where the imbalance phase is shown in the graph with a dashed line;
Figure 16 shows a histogram representative of the fatty acid composition related to OIL 3 compared to the composition of OIL 2. In Figure 16, asterisks indicate statistical significance according to Student's t-test in the difference in lipid composition between OIL 2 and OIL 3 (* p<0.05, ** p<0.005 and *** p<0.0005);
Figure 17 shows a graph representative of the number of copies of the OLE1 gene (Graph A) and of the FAD2 gene (Graph B) in the respective engineered strains compared to the wild control strain to which unit value has been attributed;
Figure 18 shows a representative graph of the expression levels of the putative gene encoding for the delta-9 desaturase enzyme activity (OLE1 - Graph A) and of the gene encoding for the delta-12 desaturase enzyme activity (FAD2 - Graph B) in the respective engineered strains with respect to the wild control strain to which unit value has been attributed;
Figure 19 shows a histogram representative of the fatty acid composition related to OIL 8 compared to the composition of OIL 3. In Figure 19, asterisks indicate statistical significance according to Student's t-test in the difference in lipid composition between OIL 8 and OIL 3 (* p<0.05, ** p<0.005 and *** p<0.0005);
Figure 20 shows a histogram representative of the fatty acid composition related to OIL 9 compared to the composition of OIL 3. In Figure 20, asterisks indicate statistical significance according to Student's t-test in the difference in lipid composition between OIL 9 and OIL 3 (* p<0.05, ** p<0.005 and *** p<0.0005).
For the purposes of the present description and of the following claims, unless indicated otherwise, all the numbers expressing quantities, values, percentages and so on must be interpreted as modified in all cases by the
term "about". Furthermore, all ranges include any combination of the maximum and minimum points described and include any intermediate range, which may or may not have been specifically listed herein.
The term “biomass” defines any substance of an organic nature that can regenerate in times compatible with its consumption, which can be used for the production of bioenergy, biofuels and biomaterials. This is in contrast to fossil biomass, whose regeneration times exceed those of consumption by many orders of magnitude.
The term “expression vector” defines a DNA construct comprising a DNA sequence linked to a control sequence capable of leading to the expression of said DNA in a suitable host. In the present invention, the typical plasmid expression vector used has: a) an origin of replication which allows the actual replication of the plasmid so that in each cell of the selected host there are 1- 2 or tens of copies of the plasmid vector, or a DNA sequence that allows the integration of the plasmid vector into a chromosome of each cell of the selected host; b) a selection marker such that a cell correctly transformed with the plasmid vector can be selected; c) a DNA sequence comprising cleavage sites for restriction enzymes in order to be able to introduce exogenous DNA into the plasmid vector by a process called ligation. As generally reported in the prior art, in order to reach high levels of expression of the gene inserted in the host cell, the coding sequence must be correctly and functionally connected to regulatory elements of the transcription, functioning in the selected expression host.
The term “transformation” used herein means that DNA, once introduced into the cell, can replicate outside chromosomes or as part of a chromosome.
The term “lipid bodies” refers to the intracellular compartments present in animals, plants, fungi and even bacteria specialised for the accumulation of energy in the form of neutral lipids such as triglycerides and sterol esters.
The term “oleaginous microorganism” refers to a microorganism capable of accumulating at least 20% of lipids with respect to its dry weight.
The term “delta-9 desaturase” refers to a polypeptide belonging to the family of enzymes EC 1.14.19.1 which catalyses the introduction of a double bond in the delta-9 position of the fatty acid chain. Such a reaction has
palmitic and/or stearic acid as its predominant substrate, giving rise to palmitoleic and/or oleic acid, respectively.
The term “delta-12 desaturase” refers to a polypeptide belonging to the family of enzymes EC 1.14.19.6 which catalyses the introduction of a double bond in the delta-12 position of the fatty acid chain. Such a reaction has oleic acid as its predominant substrate, giving rise to linoleic acid.
By way of non-limiting example of the present invention, the following examples are given to support and demonstrate the metabolic path developed by the inventors of the present invention for the production of modified oil.
EXAMPLE 1
The microbial oils with plasticising action (OIL 1 and OIL 2) were produced according to the procedures described below.
The following Table 1 shows the fatty acid composition relating to OIL 1 and OIL 2, expressed as a percentage weight by weight (% w/w) at the final time.
TABLE 1
A) Production of microbial oil with plasticising action in the oleaginous yeast Rhodosporidium toruloides DSM4444 by fermentation process
(OIL 1)
The cells of the oleaginous yeast strain R. toruloides DSM4444 were pre-
inoculated into the medium from the following composition: 1 g of yeast extract, 1.31 g (NH bO^ 0.95 Na2HP04, 2.7 g KH2PO4, 0.2 g MgS04 * 7H2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2H2O, 0.55 g FeSC>4 * 7H2O, 0.52 g citric acid, 0.10 g ZnSC>4 * 7H2O, 0.076 g MnSC>4 * H2O, 100 microlitres of H2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon. This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts. The pre inoculation was carried out in 200 ml_ of medium in 1 L flasks placed at 25 °C on an orbital shaker at 220 rpm. After 72 hours of growth, the cells were inoculated in a 2L bioreactor at an initial DO660 of approximately 1. The operating volume of medium, the same used for the pre-culture, corresponds to lOOOmL in the presence of about 40 g/L of glycerol.
After a fermentation time suitable for the development of an exponential growth phase, the imbalancing phase began, where crude glycerol was added to the medium to reach a final concentration of about 50 g/L. The C:N molar ratio therefore switches to the value of about 30:1 , causing a metabolic variation towards the accumulation of microbial oils in the so-called lipid bodies at the expense of cell divisions, which cannot be performed due to the scarcity of the nitrogen source.
The fermentation parameters require the bioreactor to maintain a constant temperature of 25 °C; an amount of dissolved oxygen greater than 25% with an air flow of 1 vvm (volume of air per volume of culture medium); the pH is maintained at 5.5 with the addition, if necessary, of NaOH 4M and H3PO4 at 25% (v/v); stirring is dependent on the percentage of oxygen dissolved in the medium.
After 264 hours from inoculation, the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids. The chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring. An equal
volume (1 :1 v/v) of a 2:1 chlorofornrmethanol solution was added to the suspension and then it was subjected to centrifugation for 10 minutes at 10000 rpm until separation in phases was obtained; the lower phase was recovered and 10 mL of 100% chloroform were added to the suspension in order to recover the remaining lipids. The microbial oil obtained from chemical extraction was subjected to a transesterification reaction and subsequent analysis with gas chromatography [SAVI LABORATORI & SERVICE S.r.l., Roncoferraro (MN), Italy]
Figure 1 shows the fermentation profile of R. toruloides with respect to the biomass trend over time (symbol ·) and the corresponding substrate consumption (symbol A), where the imbalance phase is shown in the graph with a dashed line, the line with the symbol A represents the trend of the glycerol concentration, and the line with the symbol · represents the trend of the biomass.
B) Production of microbial oil with plasticising action in the oleaginous yeast Lipomyces starkeyi DSM70295 by fermentation process (OIL 2).
The cells of the oleaginous yeast strain Lipomyces starkeyi DSM70295 were pre-inoculated into the medium from the following composition: 1 g of yeast extract, 1.31 g (NH bO^ 0.95 Na2HP04, 2.7 g KH2PO4, 0.2 g MgSC>4 * 7H2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2H2O, 0.55 g FeSC>4 * 7FI2O, 0.52 g citric acid, 0.10 g ZnSC>4 * 7FI2O, 0.076 g MnSC>4 * FI2O, 100 microlitres of FI2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon. This concentration allows a C:N molar ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts. The pre-inoculation was carried out in 200 mL of medium in 1 L flasks placed at 25 °C on an orbital shaker at 220 rpm. The cells were inoculated in a 2L bioreactor at an initial DO660 of 3. The operating volume of medium, the same used for the pre-culture, corresponds to 1000 mL in the presence of about 60 g/L of glycerol.
After a fermentation time suitable for the development of an exponential growth phase, the imbalancing phase began, where crude glycerol was added to the medium to reach a final concentration of 60 g/L. The C:N molar
ratio therefore switches to the value of about 40:1 , causing a metabolic variation towards the accumulation of microbial oils in the so-called lipid bodies at the expense of cell divisions, which cannot be performed due to the scarcity of the nitrogen source.
The fermentation parameters require the bioreactor to maintain a constant temperature of 25 °C; an amount of dissolved oxygen greater than 25% with an air flow of 1 vvm (volume of air per volume of culture medium); the pH is maintained at 5.5 with the addition, if necessary, of NaOH 4M and H3PO4 at 25% (v/v); stirring is dependent on the percentage of oxygen dissolved in the medium.
After about 160 hours from inoculation, the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids. The chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring. An equal volume (1 :1 v/v) of a 2:1 chloroforrmmethanol solution was added to the suspension and then it was subjected to centrifugation for 10 minutes at 10000 rpm until separation in phases was obtained; the lower chloroform phase was recovered and 10 mL of 100% chloroform were added to the suspension in order to recover the remaining lipids. The microbial oil obtained from chemical extraction was subjected to a transesterification reaction and subsequent analysis with gas chromatography [SAVI LABORATORI & SERVICE S.r.l., Roncoferraro (MN), Italy]
Figure 2 shows the fermentation profile of L. starkeyi with respect to the biomass trend over time (symbol ·) and the corresponding substrate consumption (symbol A), where the imbalance phase is shown in the graph with a dashed line, the line with the symbol A represents the trend of the glycerol concentration, and the line with the symbol · represents the trend of the biomass.
EXAMPLE 2
This example describes the procedure for preparing the expression
cassette containing the putative sequence encoding for the delta9 desaturase activity under the control of the pTDH3 promoter and tPGK1 terminator together with the resistance cassette to nurseotricin NsrR.
A) Construction of the recombinant expression vector pLS01 bearing the sequence that encodes for the enzyme nurseotricin N-acetyl transferase (NrsR) capable of giving resistance to the antibiotic nurseotricin.
The sequences for the pURA3 promoter and tGAL1 terminator of L. starkeyi were amplified by PCR using as a template the genomic DNA of L. starkeyi DSM70295 and specific oligonucleotides (SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO:5; SEQ ID NO:6). The NAT gene encoding for the resistance to nurseotricin was amplified by PCR using as a template the plasmid pZs and specific oligonucleotides (SEQ ID NO: 7; SEQ ID NO: 8). The program used for both amplifications is as follows: after 30 seconds of denaturation at 98 °C, 35 cycles (10 second denaturation at 98 °C, 30 second pairing at 64 °C and 30 seconds elongation at 72 °C ), followed by a final elongation of 2 minutes at 72 °C. The PCR products were loaded onto 0.8% agarose gel and the fragments of interest were recovered by excision and purified with the NucleoSpin Gel and PCR clean-up kit (MACHEREY- NAGEL GmbH & Co. KG). The NrsR gene, amplified by plasmid pZs, and pURA3 and t GAL1, amplified by the genomic DNA of L. starkeyi, were inserted into the pStblue-1 vector by cloning using the Gibson assembly cloning kit (New England Biolab, NEB) and the product amplified by transformation of Escherichia coli. Once the plasmid extraction from E. coli was performed, visualized by electrophoretic run on 0.8% agarose gel, the correct insertion of the pURA3, NAT, t GAL1 fragments in the pSTBIue plasmid was verified through analytical digestions tests carried out with the restriction enzymes Hhel and Sphl. The vector named pl_S01 -L/rsft was purified on a column using the NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG) and sequenced using the specific oligonucleotides (SEQ ID NO: 9; SEQ ID NO: 10).
Figure 3 shows the recombinant vector pl_S01 -L/rsft.
B) Construction of the recombinant vector pLS02 bearing the multiple
cloning site (MCS).
The pLS01 vector was subjected to preparative digestion with the restriction enzyme EcoRV for linearization. The vector was recovered by removal from agarose gel and then purified with NucleoSpin Gel and PCR clean-up and quantified with Nanodrop [Euroclone (Spa)]. The constitutive and strong promoter of the endogenous gene of L. starkeyi TDH3 and the terminator of the endogenous gene of L. starkeyi PGK1 were inserted in the linearized pl_S01 plasmid: these sequences were amplified by PCR using as model the genomic DNA of L. starkeyi DSM70295 and specific oligonucleotides (SEQ ID NO: 11 ; SEQ ID NO: 12; SEQ ID NO:13; SEQ ID NO:14), interspersed with specific sites for five different restriction enzymes (Bglll, Spel, EcoRV, Blpl, Fsel) in order to create an MCS between promoter and terminator. This was done again using the Gibson assembly cloning kit (New England Biolab, NEB). Once the extraction of the pl_S02 plasmid from E. coli was carried out, it was verified through an analytical gel of 0.8% agarose. The correct insertion of the p TDH3, tPGK1 fragments inside the pl_S01 -L/rsft plasmid was verified through the analytical digestions carried out with Pstl and Pmll. The vector pLS02 was purified on a column using NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG) and sequenced using the specific oligonucleotides (SEQ ID NO: 9; SEQ ID NO: 15).
Figure 4 shows the vector pLS02.
C) Construction of the recombinant vector pLS02 -OLE1 bearing the putative gene encoding for the delta-9 desaturase enzyme activity.
The sequences encoding for the enzyme delta-9 desaturase were obtained by aligning the sequence of the yeast protein Saccharomyces cerevisiae against the putative amino acid sequences of the coding sequences present in the whole genome of Lipomyces starkeyi (www.genome.jgi.doe.gov/Lipst1_1/Lipst1_1.home.html), using the BlastP program (https://blast.ncbi. nlm.nih.gov/Blast.cgi?PAGE=Protein).
The sequence encoding for the enzyme delta-9 desaturase was amplified by PCR using the genomic DNA of L. starkeyi DSM70295 as a template and specially designed oligonucleotides (SEQ ID NO: 16; SEQ ID NO:17). The
program used for amplification is as follows: after 30 seconds of denaturation at 98 °C, 30 cycles (10 second denaturation at 98 °C, 30 second pairing at 72 °C and 60 second elongation at 72 °C ), followed by a final elongation of 2 minutes at 72 °C. The PCR product and the target vector pLS02-MCS were digested with the restriction enzyme Spel and their ligation led to the obtainment of the recombinant expression vector pLS02 -OLE1. The vector pLS02 -OLE1 was removed from agarose gel and purified on a column using NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG), quantified and sequenced using the specific oligonucleotides (SEQ ID NO: 15; SEQ ID NO: 14).
Figure 5 shows the vector pl_S02 -OLE1.
D) Isolation of the expression cassette for the putative gene encoding for the delta9 desaturase activity and for resistance to nurseotricin.
The pl_S02 vector was digested with the EcoRI-HF restriction enzyme. The fragment corresponding to the expression cassette (4556 bp) was recovered by removal from 0.8% agarose gel and purified with NucleoSpin Gel and PCR clean-up.
Figure 6 shows the expression cassette for the sequence encoding for the delta9 desaturase activity ( OLE1 ).
EXAMPLE 3
This example describes the procedure for preparing the expression cassette containing the sequence encoding for the delta12 desaturase activity under the control of the pTDH3 promoter and tPGK1 terminator together with the resistance cassette to hygromycin HygR.
A) Construction of the recombinant vector pLS03 bearing the sequence encoding for the enzyme hygromvcin-B 4-O-kinase (HygR) capable of giving resistance to the antibiotic hygromycin.
The HygR gene for resistance to hygromycin B (4-O-kinase) was amplified by PCR using as a template the plasmid pZ4 and specific oligonucleotides (SEQ ID NO: 18; SEQ ID NO: 19). The program used for the amplification is as follows: after 30 seconds of denaturation at 98 °C, 35 cycles (10 second denaturation at 98 °C, 30 second pairing at 68°C and 30 second elongation
at 72 °C ), followed by a final elongation of 2 minutes at 72 °C. The PCR product was loaded onto 0.8% agarose gel and the fragments of interest were recovered by excision and purified with the NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG). The hph gene, amplified by the plasmid pZ4, was inserted into the pStblue-1 vector by cloning using the Gibson assembly cloning kit (New England Biolab, NEB). Once the plasmid extraction from E. coli was performed, visualized by electrophoretic run on 0.8% agarose gel, the correct insertion of the hph fragment in the pSTBIue plasmid was verified through analytical digestions tests carried out with the restriction enzymes Hhel and Hindi. The vector named pLS03 -HygR was purified on the column using the kit described above and sequenced using the specific oligonucleotides (SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:18).
Figure 7 shows the recombinant vector pLS03.
B) Construction of the recombinant vector pLS04 bearing the multiple cloning site (MCS).
The target vector pLS02 was digested with the restriction enzyme Nhel to obtain the linearized pl_S02 vector and remove the nurseotricin resistance gene ( NrsR ). Similarly, using the same restriction enzyme Nhel, the pl_S03 vector was digested to obtain the HygR gene, which confers resistance to the hygromycin-B antibiotic.
The HygR gene and the pl_S02 vector were recovered by removal from agarose gel and then purified with NucleoSpin Gel and PCR clean-up and quantified with Nanodrop [Euroclone (Spa)]. The ligation was then carried out which led to the obtainment of the recombinant expression vector pl_S04 bearing resistance to the antibiotic hygromycin B. The correct insertion of the HygR fragment inside the pl_S02 plasmid was verified through the analytical digestion carried out with Sacll.
Figure 8 shows the recombinant vector pl_S04.
C) Construction of the recombinant vector pLS04 -FAD2 bearing the gene encoding for the delta-12 desaturase enzyme activity.
The sequences encoding for the enzyme delta-12 desaturase were obtained from the identification and characterisation work described in
Matsuzawa, Tomohiko, et al. “Identification and characterization of D12 and D12/D15 bifunctional fatty acid desaturases in the oleaginous yeast Lipomyces starkeyi.” Applied microbiology and biotechnology 102.20 (2018): 8817-8826.
The sequence encoding for the enzyme delta-12 desaturase was amplified by PCR using the genomic DNA of L. starkeyi DSM70295 as a template and specific oligonucleotides (SEQ ID NO: 20; SEQ ID NO:21). The program used for the amplification is as follows: after 30 seconds of denaturation at 98 °C, 10 cycles (10 second denaturation at 98 °C, 30 second pairing at 59 °C and 40 second elongation at 72 °C ), 25 cycles (10 second denaturation at 98 °C, 30 second pairing at 64 °C and 40 second elongation at 72 °C), followed by a final 2 minute elongation at 72 °C. The target vector pLS04- MCS was digested with the restriction enzyme EcoRV-HF, and ligated to the PCR product leading to the obtainment of the recombinant expression vector pLS04-F4D2. The vector pLS04-F4D2 was purified on a column using NucleoSpin Gel and PCR clean-up kit (MACHEREY-NAGEL GmbH & Co. KG) and sequenced using the specific oligonucleotides (SEQ ID NO: 15; SEQ ID NO: 14).
Figure 9 shows the vector pl_S04-F4D2.
D) Isolation of the expression cassette for the gene encoding for the desaturase delta-12 activity and for resistance to hygromvcin B.
The pl_S04-F4D2 vector was digested with the restriction enzyme Xhol. The fragment corresponding to the expression cassette (4765 bp) was recovered by removal from 0.8% agarose gel and purified with NucleoSpin Gel and PCR clean-up.
Figure 10 shows the expression cassette for the sequence encoding for the delta12 desaturase activity ( FAD2 ).
EXAMPLE 4
Construction of the recombinant strain L. sfar/cey/-OLE1-FAD2 from L. starkeyi (DSM70295) for the modification of the lipid profile and for obtaining the microbial oil (OIL 3).
The laboratory strain of L. starkeyi DSM70295 was transformed using two
expression cassettes of which (i) one containing the putative sequence encoding for the delta9 desaturase activity under the control of the pTDH3 promoter and t PGK1 terminator together with the resistance cassette to nurseotricin NsrR, described in example 2, and (ii) one containing the sequence encoding for the delta12 desaturase activity under the control of the p TDH3 promoter and the t PGK1 terminator together with the hygromycin resistance cassette HygR, described in example 3. The integration of both expression cassettes was verified by PCR with the oligonucleotides (SEQ ID NO: 15; SEQ ID NO:22; SEQ ID NO:23) (Calvey et al„ “An optimized transformation protocol for Lipomyces starkeyi .’’ Current genetics 60.3 (2014): 223-230) (Figure 11).
EXAMPLE 5
Evaluation of the number of gene copies inserted in the genome of L. starke -OLE1-FAD2 through relative quantitative Real Time PCR.
The evaluation of the number of gene copies inserted in the genome of L. starkeyi-OLE1 -FAD2 was carried out through a relative quantitative Real Time PCR. Starting from the genomic DNA, extracted from both the parental strain and the engineered strain, the number of copies of OLE1 and FAD2 per cell was quantified. Real-time PCR was performed using specific oligonucleotides (SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27) and actin as internal control (SEQ ID NO: 28; SEQ ID NO: 29) (Figure 12).
EXAMPLE 6
Evaluation of the expression levels of the sequences encoding for delta-9 desaturase and delta-12 desaturase over-expressed in L. starkeyi - OLE1- FAD2 by relative quantitative Real Time PCR.
The evaluation of the expression levels of the putative sequence encoding for the enzyme delta-9 desaturase and delta-12 desaturase was performed by relative quantitative Real Time PCR.
The messengers for delta-9 desaturase and delta-12 desaturase in the recombinant strain L. starkeyi-OLE1-FAD2 and in the wild strain are
quantified from the cDNA obtained by retro-transcription of the total RNA (Figure 13).
The cells were pre-inoculated in 5 ml of the medium containing: Glucose 25%, xylose 25%, 1 g of yeast extract, 1.31 g (NH bO^ 0.95 Na2HPC>4, 2.7 g KH2PO4, 0.2 g MgSC * 7H2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2H2O, 0.55 g FeSC>4 * 7FI2O, 0.52 g citric acid, 0.10 g ZnS04 * 7H20, 0.076 g MnS04 * H2O, 100 microlitres of FI2SO4 18 M, per litre of solution) for 24 h. RNA extraction was performed on a sample of cells in the exponential phase, using the ZR Fungal/Bacterial RNA Miniprep kit (Zymoresearch/The epigenitics company). The extraction was then controlled with electrophoretic run on 1.5% agarose gel. The cDNA was obtained using the iScript cDNA Synthesis (BIORAD) kit. Real-time PCR was performed using specific oligonucleotides (SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27) and actin as internal control (SEQ ID NO: 28; SEQ ID NO: 29).
EXAMPLE 7
Flask production kinetics of the oleaginous yeast L. starkevi-OLE1 -FAD2 engineered for the modification of the lipid profile of the microbial oil obtained from the wild strain.
The cells of the oleaginous yeast strain L. starkeyi-OLE1-FAD2, engineered for the production of modified lipid oil (OIL 3) were pre-inoculated into the medium with the following composition: 1 g yeast extract, 1.31 g (NH )2S04, 0.95 Na2HP04, 2.7 g KH2PO4, 0.2 g MgS04 * 7H 0, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2H2O, 0.55 g FeS04 * 7H20, 0.52 g citric acid, 0.10 g ZnS04 * 7H20, 0.076 g MnS04 * FI2O, 100 microlitres of FI2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon. This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts. The pre-inoculation was carried out in 100 mL of medium in 500L flasks placed at 25 °C on an orbital shaker at 220 rpm. After 72 hours of growth, the cells were inoculated at an optical density of 3 (OD 660 nm) in 50 mL of medium, the same used
for pre-inoculation in the presence of about 100 g/L of glycerol, in 250 imL flasks placed at 25 °C on an orbital shaker at 220 rpm. Cell growth was monitored by measuring OD at 660 nm at regular time intervals. The extracellular concentration of glycerol was determined by HPLC using H2SO4 0.01 M as mobile phase and a Rezex ROA-Organic (Phenomenex) column.
After 240 hours from inoculation, the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids. The chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring. An equal volume (1 :1 v/v) of a 2:1 chloroforrmmethanol solution was added to the suspension and then it was subjected to centrifugation for 10 minutes at 10000 rpm until separation in phases was obtained; the lower phase was recovered and 10 mL of 100% chloroform were added to the suspension in order to recover the remaining lipids. The microbial oil obtained from chemical extraction was subjected to a transesterification reaction and subsequent analysis with gas chromatography [SAVI LABORATORI & SERVICE S.r.l., Roncoferraro (MN), Italy].
Figure 14 shows the fermentation profile of the L. starkeyi-OLE1-FAD2 strain with respect to the biomass trend over time and the corresponding substrate consumption. The following Table 2 shows the fatty acid composition relating to OIL 3 compared with the composition of OIL 1 and 2 and of some vegetable oils, in particular castor oil (OIL 4), sunflower oil AP- 75® (Cargill) (OIL 5), sunflower oil AP-88® (Cargill) (OIL 6).
TABLE 2
The following table 3 summarises the characterisation of the oils of Table 2 and of a mineral oil MES (TUDALEN 4226, H&R Group) (OIL 7) as a functional reference carried out using Differential Scanning Calorimetry (DSC), starting from a temperature of -140 °C to +60 °C to establish the melting temperature and the glass transition temperature. The iodine number was determined using the ISO 3961 method, which involves treating the oil with an excess Wijs solution. Wijs solution contains iodine monochloride dissolved in acetic acid. The iodine monochloride reacts with the unsaturated part of the oil and the unreacted iodine is released as iodine by adding potassium iodide. The released iodine is determined by titration with sodium thiosulfate.
TABLE 3
EXAMPLE 8
Production of microbial oil (OIL 3) with plasticising action in the oleaginous yeast L. starkevi-OLE1 -FAD2 by a fermentation process in a bioreactor with a volume of 10 litres.
The cells of the oleaginous yeast strain L. starkeyi-OLE1-FAD2, engineered for the production of modified lipid oil (OIL 3) were pre-inoculated into the medium with the following composition: 1 g of yeast extract, 1.31 g (NH )2S04, 0.95 Na2HP04, 2.7 g KH2PO4, 0.2 g MgS04 * 7H 0, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCL * 2H2O, 0.55 g FeS04 * 7H20, 0.52 g citric acid, 0.10 g ZnS04 * 7H20, 0.076 g MnS04 * H2O, 100 microlitres of H2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon. This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts. The pre-inoculation was carried out in 200 mL of medium in 1000L flasks placed at 25 °C on an orbital shaker at 220 rpm. After about 48 hours of growth, the cells were inoculated in a 10L bioreactor at an initial DO660 of 0.2. The operating volume of medium, the same used for the pre-culture, corresponds to 5000mL in the presence of about 25g/L of glycerol. The operating volume of medium used in the bioreactor is 5000mL.
After a fermentation time suitable for the development of an exponential growth phase, the imbalancing phase began, where crude glycerol was
added to the medium to reach a final concentration of about 80 g/L. The C:N molar ratio therefore switches to the value of about 50:1 , causing a metabolic variation towards the accumulation of microbial oils in the so-called lipid bodies at the expense of cell divisions, which cannot be performed due to the scarcity of the nitrogen source.
The fermentation parameters require the bioreactor to maintain a constant temperature of 25 °C; an amount of dissolved oxygen greater than 25% with an air flow of 1 vvm (volume of air per volume of culture medium); the pH is maintained at 5.5 with the addition, if necessary, of NaOH 4M and H3PO4 at 25% (v/v); stirring is dependent on the percentage of oxygen dissolved in the medium.
After 150 hours from inoculation, the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids. The chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring. An equal volume (1 :1 v/v) of a 2:1 chloroforrmmethanol solution was added to the suspension and then it was subjected to centrifugation for 10 minutes at 10000 rpm until separation in phases was obtained; the lower chloroform phase was recovered and 10 mL of 100% chloroform were added to the suspension in order to recover the remaining lipids. The microbial oil obtained from chemical extraction was subjected to a transesterification reaction and subsequent analysis with gas chromatography [SAVI LABORATORI & SERVICE S.r.l., Roncoferraro (MN), Italy]
Figure 15 shows the fermentation profile of L. starkeyi-OLE1-FAD2 with respect to the biomass trend over time and the corresponding substrate consumption.
EXAMPLE 9
Production kinetics of oils in flasks with the oleaginous yeast L. starkevi- OLE1-FAD2 engineered for the modification of the lipid profile of the oil obtained with respect to the wild strain.
The cells of the oleaginous yeast strain L. starkeyi-OLE1-FAD2, engineered for the production of modified lipid oils (OIL 3) were pre inoculated into the medium with the following composition: 1 g yeast extract, 1.31 g (NH )2S04, 0.95 Na2HP04, 2.7 g KH2PO4, 0.2 g MgS04 * 7H 0, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCL * 2H2O, 0.55 g FeS04 * 7H2O, 0.52 g citric acid, 0.10 g ZnS04 * 7H2O, 0.076 g MnS04 * H2O, 100 microlitres of H2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon. This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts. The pre-inoculation was carried out in 100 mL of medium in 500L flasks placed at 25 °C on an orbital shaker at 220 rpm. After 72 hours of growth, the cells were inoculated at an optical density of 3 (OD 660 nm) in 50 mL 20 of medium, the same used for pre-inoculation in the presence of about 100 g/L of glycerol, in 250 mL flasks placed at 25 °C on an orbital shaker at 220 rpm. Cell growth was monitored by measuring OD at 660 nm at regular time intervals. The extracellular concentration of glycerol was determined by HPLC using H2SO4 0.01 M as mobile phase and a Rezex ROA-Organic (Phenomenex) column. After 240 hours from inoculation, the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids. The chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring. An equal volume (1 :1 v/v) of a 2:1 chloroforrmmethanol solution was added to the suspension and then it was subjected to centrifugation for 10 minutes at 10000 rpm until separation in phases was obtained; the lower phase was recovered and 10 mL of 100% chloroform were added to the suspension in order to recover the remaining lipids. The microbial oil obtained from chemical extraction was subjected to a
transesterification reaction and subsequent analysis with gas chromatography [SAVI LABORATORI & SERVICE S.r.l., Roncoferraro (MN), Italy].
Figure 16 shows the composition of fatty acids relating to OIL 3 compared to the composition of OIL 2.
EXAMPLE 10
Construction of the recombinant strain L. starkevi- OLE1 from L. starkevi (DSM70295) for the modification of the lipid profile and for obtaining the microbial oil (OIL 8).
The laboratory strain of L. starkeyi DSM70295 was transformed using the expression cassette containing the putative sequence encoding for the delta9 desaturase activity under the control of the pTDH3 promoter and tPGK1 terminator together with the nurseotricin NsrR resistance cassette, described in Example 2.
EXAMPLE 11
Construction of the recombinant strain L. starkevi- FAD2 from L. starkevi (DSM70295) for the modification of the lipid profile and for obtaining the microbial oil (OIL 9).
The laboratory strain of L. starkeyi DSM70295 was transformed using the expression cassette containing the sequence encoding for the delta12 desaturase activity under the control of the pTDH3 promoter and tPGK1 terminator together with the hygromycin HygR resistance cassette, described in Example 3.
EXAMPLE 12
Evaluation of the number of gene copies inserted in the genome of L. starkevi- OLE1 and L. starkevi- FAD2 through relative quantitative Real Time PCR.
The evaluation of the number of gene copies inserted in the genomes of L. starkeyi- OLE1 and L. starkeyi- FAD2 was carried out through a relative quantitative Real Time PCR, as described in Example 5. Starting from the
genomic DNA, extracted from both the parental strains and the engineered strains, the number of copies of OLE1 and FAD2 per cell was quantified. Real-time PCR was performed using specific oligonucleotides (SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27) and actin as internal control (SEQ ID NO: 28; SEQ ID NO: 29) (Figure 17).
EXAMPLE 13
Evaluation of the expression levels of the sequences encoding for delta- 9 desaturase and delta-12 desaturase over-expressed in the L. starkevi- OLE1 and L. starkevi- FAD2 strains by relative quantitative Real Time PCR.
The evaluation of the expression levels of the putative sequence encoding for the enzyme delta-9 desaturase and delta-12 desaturase was performed by relative quantitative Real Time PCR, as described in Example 5.
The messengers for delta-9 desaturase and delta-12 desaturase in the recombinant strains L. starkeyi- OLE1 , L. starkeyi- FAD2 and in the wild strain are quantified from the cDNA obtained by retro-transcription of the total RNA (Figure 18).
The cells were pre-inoculated in 5 ml of the medium containing: Glucose 25%, xylose 25%, 1 g of yeast extract, 1.31 g (NFl4)2S04, 0.95 Na2FIP04, 2.7 g KFI2PO4, 0.2 g MgS04 * 7FI2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCl2 * 2FI2O, 0.55 g FeS04 * 7H2O, 0.52 g citric acid, 0.10 g ZnS04 * 7H20, 0.076 g MnS04 * H2O, 100 microlitres of FI2SO4 18 M, per litre of solution) for 24 h. RNA extraction was performed on a sample of cells in the exponential phase, using the ZR Fungal/Bacterial RNA Miniprep kit (Zymoresearch/The epigenitics company). The extraction was then controlled with electrophoretic run on 1.5% agarose gel. The cDNA was obtained using the iScript cDNA Synthesis (BIORAD) kit. Real-time PCR was performed using specific oligonucleotides (SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27) and actin as internal control (SEQ ID NO: 28; SEQ ID NO: 29).
EXAMPLE 14
Production kinetics of oil in flasks of the oleaginous yeasts L. starkevi - OLE1 and L. starkevi -FAD2, engineered for the modification of the lipid profile of the oil with respect to the wild strain.
The cells of the oleaginous yeast strains L. starkeyi-O El and L. starkeyi- FAD2, engineered for the production of oils with a modified lipid profile (OIL 8 and OIL 9) were pre-inoculated in the medium with the following composition: 1 g yeast extract, 1.31 g (NH bO^ 0.95 Na2HP04, 2.7 g KH2PO4, 0.2 g MgS04 * 7H2O, per litre enriched with mineral stock 100 times concentrated, containing (4 g CaCL * 2H2O, 0.55 g FeS04 * 7H2O, 0.52 g citric acid, 0.10 g ZnS04 * 7H2O, 0.076 g MnS04 * H2O, 100 microlitres of H2SO4 18 M, per litre of solution), in the presence of glycerol 15 g/L as a source of energy and carbon. This concentration allows a C:N ratio of 10:1 to be obtained, which is defined as balanced to support the growth and division of yeasts. The pre-inoculation was carried out in 100 mL of medium in 500L flasks placed at 25 °C on an orbital shaker at 220 rpm. After 72 hours of growth, the cells were inoculated at an optical density of 3 (OD 660 nm) in 50 mL 20 of medium, the same used for pre-inoculation in the presence of about 100 g/L of glycerol, in 250 mL flasks placed at 25 °C on an orbital shaker at 220 rpm. Cell growth was monitored by measuring OD at 660 nm at regular time intervals. The extracellular concentration of glycerol was determined by HPLC using H2SO40.01 M as mobile phase and a Rezex ROA-Organic (Phenomenex) column. After 240 hours from inoculation, the cells were recovered by centrifugation and subjected to acid lysis (HCI 2M), in order to break the cells themselves, and treatment with 2:1 chloroforr methanol solution and chloroform 100% for the separation of the lipids. The chemical extraction of the oil was carried out according to the following protocol: the cells were dissolved in a hydrochloric acid solution 2 M; the preparation was heated in a thermostated bath for 60 minutes at 95 °C with constant stirring. An equal volume (1 :1 v/v) of a 2:1 chloroforrmmethanol solution was added to the suspension and then it was subjected to centrifugation for 10 minutes at 10000 rpm until separation in phases was obtained; the lower phase was recovered and 10 mL of 100% chloroform were added to the suspension in order to recover the remaining lipids. The
microbial oil obtained from chemical extraction was subjected to a transesterification reaction and subsequent analysis with gas chromatography [SAVI LABORATORI & SERVICE S.r.l., Roncoferraro (MN), Italy]. Figures 19 and 20 show the compositions of fatty acids relating to OIL 8 and OIL 9 compared with the composition of OIL 3.
LIST OF OLIGONUCLEOTIDE SEQUENCES
SEQ ID NO: 1 OLE1
AT GACTGCCAGTGCT G AG ACAACGT CCGCGCAGCCT GT CGT CG AGT CGGCT CGCGCAAGGCCACCCAG AT CAAGCT CAACGT CGCCTT CT CG TT CGGTTGGT AGT GCTGCGT CG ACTGCG AAGCAAGCGT CT CCT ACAT T CGT CCACAT CT CCG AGCAACCGTT CACT CT CCAG AACTGGT ACAAG CACAT CAGCTGGCT CAAT GT CACGCT GAT CAT CTT CAT CCCT GT CATT GGCTGCACT ACCGCGGTTTT CACT CCT CTGCAAT CT AAG ACTGCCAT CCTTGCCTTT GT CT ACT ACGCCCT GACGGGCCT CGGT AT CACTGCGG GTT AT CACCGCCT CTGGT CGCACCGTGCTT ACAGTGCCCGT CTT CCT CT CCGT ATT CT ACT CGCT GCTTT CGGCGGCGGTGCT GTT GAGGGTT C CATT CGCTGGTGGT CCGCTGGT CACCGT GT CCAT CACAGATT CACCG AT ACT GAG AAGG ACCCTT ACT CT GT CCGCAAGGGT CTGCT CT ATT CT CACATGGGCTGG ATGGT GTTT CT CCACAACCCCAAG AAGT CCGGCC GGGT CG AT AT CACCG ACTT G AACGCT G ACCCT GT CGT CAG ATGGCAG CACAAG AACT ACATT CT CGT CCTT CT CTTT AT GGGTTT CAT CTT CCCC AT GGT AGTTGCCGGCCT CGG ATGGGGT G ACTGG AAGGGTGGT CT CA T CTGGGCTGGCATT GT CCGTTT G ACAGTT GT CCACCATGCCACTTTTT GT GT CAACT CGCT CGCT CACTGGCT CGGT G ACCAGCCTTT CG ACG AC CGCCGCT CT CCGCGT G ACCACTT CTT G ACTGCCAT CGTT ACGTT CGG CG AGGGCT AT CACAACTT CCACCAT G AGTT CCCCT CT G ACT ACCGT A ACGCCAT AAG ATGGT AT CAGT AT GAT CCCACT AAGTGGCT CAT CTGG TT CCT CAAG AAG AT CGGCTTTGCTT AT G ACCTT AAG ACCTT CT CT CAC AATGCCAT CCAGCAAGGCCT CGT CCAGCAG AGGCAG AAAAAGCT CG ACAAGTGGCGCGCACGT CTT AACTGGGGT GTT CCT CT CG AGCAGCT C CCGGT CATGG AATTT G AAGAGT ACCAGGAGCAGGCCAAG ACGCGT G CGCT CGT CCT CATT GCTGGT GTT GT CCACG AT GT CACCAACTTT ATT G AGCAGCAT CCTGGT GG AAAGGCT CT GAT CCAGT CAGGT ATTGGCAAG G ATGCCACCGCT GT CTT CAATGGCGGT GT CT ACG ACCACT CCAATGC TGCCCACAACCTGCT CGGT ACCATGCGT GTTGGT GT CATT CGCGGCG GCAT GG AAGT CGAGGT CT GG AAG AT GGCT CAGCG AG AG AAT AAGG A GT CAACG AT CAAGT CCG ATT CG AAT AATGCCAAT AT CGT CCGTGCAG
GTT CT CAGGCAACCCGG AT ACAAGCT CCCAT CCAGGGCGCT GGTGC CGCTTAG
SEQ ID NO: 2 FAD2
AT GT CCACAAT AACAT ACACACAGCGCAGGCCGT CAGT GT CGCT G AC TT CG AAGCCCGT CT ACAAGG ATGCCTT CGGCCACG ACTT CG AACCGC CGG AGT ACACAAT CAAAG AT AT CCTT G ATGCCAT CCCCAAGCACTGC TT CG ACCGCT CT CTT AGCCACT CT CT CGCCT AT GT CGCCCGCG ACCT CTT CT ACGCCT CCTGCTT GTT CGGCCT AGCG ACACAG AT CCAT AGCA T CCCCT AT CT ACCT GCCCGCGT CGT CGCCTGGGTT CT CT ACGGCTTT TGCCAAGGCCTT GT CGGCACAGGCTT GTGGGT CCT CGCCCACG AGT GCGGCCAT GG AGCCTT CT CCCCCT ACAAGCT CGCCAACG ACGT CGT CGGGTGGCT CCT CCACT CCGCCCT CTTT GTGCCGT ACCACT CATGGC GG AT CACT CACT CCAAGCACCACAAAGCCACCGGCCACCT CACCCG CG AT ATGGT CTT CGT CCCGCGCG ACGT G ACCCGTT ACAAGCT CT CCC G AAACCT G ACT G AGCT CACCG AGGAGGCGCCG AT CGCG ACCCT CT A TTT CCT ATTT AT CCAGCAGGT CTTT GGTTGGCCCGCGT ACCT CGCCT A CAAT GT CACCGGCCAG AAAT ACCCTGGT GT GT CCAGCTT CAG ACGGT CACATTTTGCGCCGT CCGCGCCCAT GTT CG AT GT AAAGG ACTT CTGG GAT ATT AT AAT CT CCG AT GT CGGT AT ACTT GT CGCCGGCACT CTT ACC T ATCTCG G CAT CC AG AAAT GGGGTTGGGCT A ACTT CG CTCTCTACT A CTTT AT CCCTT AT CT CTGGGT CAACAACTGGTT GGTTTGCAT CACGT A T CT ACAGCACACT G ACCCAACT CT ACCCCATT ACG ACGCGAGCG AGT GG AACTTTGCCCGCGGCGCCGCGGCAACAGT AG AT CGCG ACTTTGG CTT CAT CGGCCGCCACCT CTT CCACG AGAT CAT CG AG ACGCAT GT CG CGCACCACT ACT CGT CGCG AATT CCATT CT ACCACGCCG AGG AGGCC ACGCAAGCCAT CCGCAAGGT CATGGGCAAGCATT ACCGT CAGG ACA AG ACAAACCT CATT CT CGCACT CTGG AAGACCGCGCGG ACATGCCAT TTT GTGGAGGGCG ACGGCGT CAAG AT GT ACAG AAATGCCAACGGAAT CGGT ATT CCGCCAAAGG AGGGAAGAAGGGCT CAGT AA
SEQ ID NO: 3; pURA3 fw
TCG ATC CAG AAT TCG TGA TTC TAG ACT CGA GAT ATC ATG ATC
ACT GAG CGA TAG TTC
SEQ ID NO: 4; pURA3 rev
TCG TCA AGA GTG GTA CCC ATG TTG AAT TTA GGG ATA TAC TGT AGA AGA C
SEQ ID NO: 5;tGAL1 fw
TGA GCA TGC CCT GCC CCT AAA GTT TAG AGA TGT ACA AGG GGT SEQ ID NO: 6; tGAL1 rev
GCT TGT CGA CGA ATT CAG ATT GCC ACG ATA ACT TTG TGC
SEQ ID NO: 7; NsrR fw ATG GGT ACC ACT CTT GAC GAC
SEQ ID NO: 8; NsrR rev
TTA GGG GCA GGG CAT GCT CA
SEQ ID NO: 9; T7 ATT TAG GTG ACA CTA TAG
SEQ ID NO: 10; SP6
TAA TAC GAC TCA CTA TAG GG SEQ ID NO: 11 ; pTDH3 fw
CGT GAT TCT AGA CTC GAG ATT TAA TTT GCT GAA GCG GTT TGC SEQ ID NO: 12; pTDH3 rev
CGC TTA GCG ATA TCA CTA GTA GAT CTT GCG AAT GTG GAT TAG AGT AAG A
SEQ ID NO: 13; p PGK1 fw
ACT AGT GAT ATC GCT AAG CGG CCG GCC CTC CCG TTA ATG TTG
GGA TTC
SEQ ID NO: 14; t PGK1 rev
TAT CGC TCA GTG ATC ATG ATC CTG TCA ATT ATG CTA CCA CTT G
SEQ ID NO: 15; LsTDH3 fw ATA ATA ATC CGA ACT GCC GC SEQ ID NO: 16; OLE1 fw
TCA GAT ACT AGT ATG ACT GCC AGT GCT GAG ACA ACG TCC
SEQ ID NO: 17; OLE1 rev
AGA TAC ACT AGT CTA AGC GGC ACC AGC GCC CT
SEQ ID NO: 18; HygR fw
ATG GGT AAAAAG CCT GAA CTC ACC
SEQ ID NO: 19; HygR rev TTA TTC CTT TGC CCT CGG ACG
SEQ ID NO: 20; FAD2 fw
CTA GTA AAC TAG TAT GTC CAC AAT AAC ATA CAC AC SEQ ID NO: 21 ; FAD2 rev
TAT TCT ACT AGT TTA CTG AGC CCT TCT TCC
SEQ ID NO: 22; OLE1 CNT rev CAA CTA CCA TGG GGA AGA TG
SEQ ID NO: 23 FAD2 CNT rev
CAA GTA TAC CGA CAT CGG AGA TTA
SEQ ID NO: 24 OLE1 RT fw CCA CTT CTT GAC TGC CAT GC
SEQ ID NO: 25 OLE1 RT rev GAG GAA CCA GAT GAG CCA CT
SEQ ID NO: 26 FAD2 RT fw GAT CGC GAC TTT GGC TTC AT SEQ ID NO: 27 FAD2 RT rev
GAA TTC GCG ACG AGT AGT GG
SEQ ID NO: 28 ACT fw CAT TGC CGA CAG AAT GCA GA
SEQ ID NO: 29 ACT rev
ACG GAG TAC TTA CGC TCA GG
Claims
1. A process of engineering an oleaginous microorganism comprising the following steps of:
(a) providing an oleaginous microorganism;
(b) inserting the gene encoding the enzyme delta-9 desaturase into the oleaginous microorganism;
(c) inserting the gene encoding the enzyme delta-12 desaturase into the oleaginous microorganism;
(d) selecting the resulting engineered microorganism.
2. Process of engineering an oleaginous microorganism according to claim 1 , wherein said oleaginous microorganism is an oleaginous yeast selected from the group consisting of the genera Cryptococcus, Lipomyces, Rhodosporidium, Rhodotorula, Trichosporon, and Yarrowia.
3. Process of engineering an oleaginous microorganism according to claim 1 , wherein said oleaginous microorganism belongs to strains of the species Cryptococcus curvatus, Lipomyces starkeyi, Rhodosporidium toruloides, Rhodotorula glutinis, Trichosporon fermentans, and Yarrowia lipolytica.
4. Process of engineering an oleaginous microorganism according to claim 1 , wherein said oleaginous microorganism is Lipomyces starkeyi.
5. Process of engineering an oleaginous microorganism according to claim 1 , wherein said oleaginous microorganism is a microalgae selected from the group consisting of Chlorella ellipsoidea, Chlorella protothecoides, Chlorella vulgaris, Dunaliella sp., Haematococcus pluvialis, Neochloris oleoabundans, Neochloris oleabundans, Pseudochlorococcum sp., Scenedesmus obliquus, Tetraselmis chui, Tetraselmis sp., Tetraselmis tetrathele, Chaetoceros calcitrans CS 178, Chaetoceros gracilis, Chaetoceros muelleri, Nitzschia of. pusilla YSR02, Phaeodactylum tricornutum F&M-M40, Skeletonema sp. CS 252, Thalassiosira pseudonana CS 173 Crypthecodinium cohnii, Isochrysis sp.., Isochrysis sp., Isochrysis zhangjiangensis, Nannochloropsis oculate,
Nannochloropsis oculata NCTU-3, Nannochloropsis sp., Pavlova salina CS 49, Rhodomonas sp., and Thalassiosira weissflogii.
6. Process of engineering an oleaginous microorganism according to claim 1 , wherein said oleaginous microorganism is selected from the group consisting of fungi and protists, preferably Aspergullus terreus, Claviceps purpurea, Tolyposporium, Mortierella alpina, Mortierella isabellina, and Schizochitrium limacynum.
7. Process of engineering an oleaginous microorganism according to claim
1 , wherein said gene encoding the enzyme delta-9 desaturase overexpressed in yeast is OLE1 of Lipomyces starkeyi having the sequence (SEQ ID N: 1).
8. Process of engineering an oleaginous microorganism according to claim
1 , wherein said gene encoding the enzyme delta-12 desaturase, overexpressed in yeast is FAD2 of Lipomyces starkeyi having the sequence (SEQ ID N:2).
9. The engineered oleaginous microorganism obtained by the process according to any one of claims 1 to 8, wherein the engineered oleaginous microorganism comprises a carbon flow directed towards the synthesis of oil with a modified lipid profile compared to the wild oleaginous microorganism.
10. A process for the production of a plasticising oil which comprises the following steps:
(a) cultivation of engineered oleaginous microorganisms obtained by the process according to any one of claims 1 to 8 in a culture medium comprising biomass containing a carbon to nitrogen molar ratio between 5 and 20;
(b) imbalance by variation of the carbon to nitrogen molar ratio at values equal to or greater than 30, preferably between 30 and 100;
(c) separation of engineered oleaginous microorganisms from the culture medium; and
(d) extraction of the oil from oleaginous microorganisms.
11. Process according to claim 10, wherein said biomass comprises at least one source of organic carbon selected from the group consisting of crude glycerol, molasses, lignocellulose, sugar beet pulp, whey, starch residues, waste water, waste oils, glucose, xylose, arabinose, fructose, galactose, mannose, acetate, and/or a combination thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT202000006715 | 2020-03-31 | ||
PCT/IB2021/052620 WO2021198904A1 (en) | 2020-03-31 | 2021-03-30 | Process of engineering an oleaginous microorganism |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4127201A1 true EP4127201A1 (en) | 2023-02-08 |
Family
ID=71784374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21722286.8A Pending EP4127201A1 (en) | 2020-03-31 | 2021-03-30 | Process of engineering an oleaginous microorganism |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4127201A1 (en) |
CN (1) | CN116034164A (en) |
WO (1) | WO2021198904A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116355919B (en) * | 2021-12-28 | 2024-03-19 | 天津大学 | Escherichia coli strain for high-yield flavin mononucleotide, construction method and application |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1766023T3 (en) * | 2004-06-04 | 2011-04-29 | Fluxome Sciences As | Metabolically engineered cells for the production of polyunsaturated fatty acids |
US7465564B2 (en) * | 2004-08-10 | 2008-12-16 | E.I. Du Pont De Nemours And Company | Production of γ-linolenic acid in oleaginous yeast |
JP7144004B2 (en) * | 2018-08-23 | 2022-09-29 | 国立研究開発法人産業技術総合研究所 | Δ12 fatty acid desaturase |
-
2021
- 2021-03-30 WO PCT/IB2021/052620 patent/WO2021198904A1/en unknown
- 2021-03-30 EP EP21722286.8A patent/EP4127201A1/en active Pending
- 2021-03-30 CN CN202180024251.1A patent/CN116034164A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021198904A1 (en) | 2021-10-07 |
CN116034164A (en) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12006504B2 (en) | Production of DHA and other LC PUFAs in plants | |
US10920233B2 (en) | Compositions and methods for lipid production | |
CN100591773C (en) | Production of polyunsaturated fatty acids in oleaginous yeasts | |
CN101679990B (en) | Delta-8 desaturases and their use in making polyunsaturated fatty acids | |
US20060156435A1 (en) | Fatty acid desaturases from fungi | |
Okuda et al. | Eicosapentaenoic acid (EPA) production by an oleaginous fungus Mortierella alpina expressing heterologous the Δ17‐desaturase gene under ordinary temperature | |
EP1733029A2 (en) | Pufa-pks genes from ulkenia | |
AU2014236763B2 (en) | Thioesterases and cells for production of tailored oils | |
JP2021520821A (en) | Recombinant yeast strains that produce nervonic acid and their use | |
US10081821B2 (en) | Methods for efficient production of polyunsaturated fatty acids (PUFA) in Rhodosporidium and Rhodotorula species | |
US9303264B2 (en) | Photosynthetic microorganisms expressing thermostable lipase | |
CN108779476A (en) | The production of alpha-olefin | |
US20140256927A1 (en) | Increasing the lipid content in microalgae by genetically manipulating a triacylglycerol (tag) lipase | |
US20140275586A1 (en) | Thioesterases and cells for production of tailored oils | |
EP4127201A1 (en) | Process of engineering an oleaginous microorganism | |
FR3005317A1 (en) | MUTANT YEAS CAPABLE OF PRODUCING UNUSUAL FATTY ACID | |
WO2017195505A1 (en) | Method for producing lipid | |
US20090249516A1 (en) | Diacylglycerol acyltransferases from flax | |
EP3268457A1 (en) | Microorganisms for fatty acid production using elongase and desaturase enzymes | |
JP6723002B2 (en) | Oil and fat manufacturing method | |
WO2021198895A1 (en) | Manufacture of elastomeric compounds comprising oils with a plasticising action obtained from oleaginous microbial cells | |
Nguyen | Developing tools to genetically engineer the microalga Nannochloropsis | |
US20140289908A1 (en) | Gene combinations for producing punicic acid in transgenic plants | |
CA2810336A1 (en) | Gene combinations for producing punicic acid in transgenic plants | |
ZA200409749B (en) | Fatty acid desaturases for fungi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221013 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |